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II 
Abstract  
 
This report aims to describe, how through my academic and professional life, I have developed 
a set of skills that allow me to apply for a “Hortofruticultura” Master’s degree. After finishing 
my 5 years degree in 2005, I worked for Jardim Vista SA as an Agronomist, afterwards I went 
to the UK where I worked as a Research Technician/Research Assistant for 9 years. In September 
2016 I started working as a lab technician in Universidade do Algarve for 6 months. More 
recently, in April 2017, I joined the Syngenta team in Moncarapacho as a Senior Grower and 
Quality Management Designate. In the UK, I took part in several scientific projects, mainly 
related to molecular biology. Considering that I have been involved in completely different 
scientific subjects in these 9 years, I decided to talk about some of the molecular biology 
techniques that I have learnt throughout these years and that are also used in Molecular Farming. 
With an increase in the world population, the impact of climate change and its effect on plant 
pathogens and plant diseases there is a need for healthy plants with a high production and better 
yields to fulfil those needs. Development of modified plants has progress through plant breeding 
and biotechnology that plays a major role in understanding how to modify plant genome or plant 
physiology to respond to those needs. By sequencing and studying the plants genome it is 
possible to understand and manipulate the characteristics of plants. Molecular farming, produces 
valuable proteins, peptides and small molecules through the use of both these techniques, plant 
molecular breeding and biotechnology. 
Some routine molecular biology techniques used in plant biotechnology are common to the 
projects where I participated and are described in this report, namely DNA extraction, PCR, 
colony PCR, agarose gel electrophoresis, bacterial genetic transformation, protein expression, 
SDS-PAGE and Western Blot. These techniques are the base for the study of better ways to 
improve plants, preparing agriculture for the actual and future challenges.  
Keywords: Molecular biology, biotechnology, agriculture, plant breeding, molecular farming.  
 
 
 
 
 
 
 
III 
Resumo 
 
O objetivo deste trabalho é descrever a minha formação e aptidões adquiridas ao longo do meu 
percurso profissional, e como estas contribuíram para o desenvolvimento das minhas 
competências, as quais me permitem requerer o grau de Mestre. Após concluir o meu curso de 
5 anos letivos em 2005 fui trabalhar como Engenheira Agrónoma para a empresa Jardim Vista 
SA. Posteriormente fui para o Reino Unido onde trabalhei como Técnica de 
Laboratório/Assistente de Laboratório durante 9 anos. Em Setembro de 2016 comecei a 
trabalhar como técnica de laboratório na Universidade do Algarve. Mais recentemente, em 
Abril de 2017 integrei a equipa da Syngenta em Moncarapacho como Senior Grower e Quality 
Management Designate. No Reino Unido, fui colaboradora de vários projetos científicos, os 
quais estavam maioritariamente relacionados com a área da biologia molecular. Considerando 
que durante estes 9 anos fiz parte de projetos que abordavam temas completamente diferentes, 
decidi abordar algumas das técnicas de biologia molecular que aprendi ao longo destes anos e 
que também são usadas na área da Agricultura Molecular e Melhoramento de Plantas. Com o 
nível de população a aumentar e o impacto das alterações climáticas, a necessidade de produzir 
plantas sem elementos patogénicos e destas serem mais produtivas e atingir elevadas produções, 
e eventualmente apresentarem resistência a herbicidas, assim como a produção de proteínas de 
interesse específico (Agricultura Molecular) também aumentou. O melhoramento de plantas 
em conjunto com a Biotecnologia têm um papel extremamente importante na compreensão e 
na descodificação da informação do DNA associado a estas necessidades, pois através da 
manipulação genética é possível alterar o genoma das plantas de modo a satisfazer as exigências 
atuais. Com o estudo do genoma das plantas é possível perceber e manipular as características 
que pretendemos alterar e melhorar. “Molecular farming” produz proteínas, péptidos e 
pequenas moléculas bastante valiosas, resultado dos estudos de melhoramento de plantas 
acoplado aos progressos na área da biotecnologia. Algumas das técnicas utilizadas em 
biotecnologia descritas nesta tese são a extração de DNA, o PCR, o colony PCR, a eletroforese, 
a transformação genética, a expressão proteíca, SDS-PAGE e Western Blot. Estas técnicas 
permitem-nos estudar métodos mais eficazes de melhorar as plantas para que a agricultura 
esteja melhor preparada para os desafios atuais e futuros.  
Palavras-chave: Biologia molecular, biotecnologia, agricultura, melhoramento de plantas, 
agricultura molecular. 
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I - Introduction 
After approval from the “Comissão de Mestrado em Hortofruticultura” as a candidate for the 
Masters, it was decided that the candidate had to write and present her report, describing the 
professional competences acquired after a five-years degree completed at Universidade do 
Algarve. After finishing her degree the candidate worked for Jardim Vista SA as an Agronomist 
Engineer for almost 2 years. Afterwards the candidate went to work in the UK for 9 years as a 
Research Technician/Research Assistant in the University of Leicester, working on several 
projects (this will be explained in detail in section III). In September of 2016 the candidate 
started working as a lab technician in Universidade do Algarve. Due to the experience of the 
candidate in the laboratory, the theme chosen by the candidate was “Molecular biology 
techniques – A brief correlation between applied techniques in translational science and plant 
agriculture” that pretend to describe the acquired knowledge in molecular biology techniques, 
tools that are used in the lab to ameliorate the plants in a biotechnological context. A brief 
explanation on how biotechnology may be used to improve plants in the present and in the 
future, plant breeding and what is molecular farming and the issues around bio-safety will also 
be described.  
In section II are described some of the technique the candidate has performed on the projects 
where she participated and that are relevant for plant biotechnology: DNA extraction, PCR, 
agarose gel electrophoresis, bacterial genetic transformation, protein expression, SDS-PAGE 
and Western Blot. In this section it will be discussed each of these techniques.  
In section III it will be explained in detail the curriculum vitae, the projects in which the 
candidate participated, responsibilities and techniques learned by the candidate over the past 
twelve years. Articles where the candidate was co-author can also be found in section III.  
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II – Molecular biology techniques – A brief 
correlation between applied techniques in 
translational science and plant agriculture  
1. Biotechnology role in crop development 
 
Plants provide us with fibre, food, fuel and with one of the most important elements to sustain 
life, oxygen. But evolution to human population growth and the changing environmental 
conditions make us look at other alternatives for the use of plants. Climate changes is one of 
the most talked about and feared subject of the 21st century, and changes affect agriculture in 
many ways, and are notable in different systems in different regions of the world (Watkins, 
2007). Agriculture is the most vulnerable sector to weather and climate change and in addition 
the majority of people involved in agriculture are poorer that urban population. Some of the 
major threats of global warming, are the unpredictable temperature and sea level rise. These 
threats affect plant agriculture in many ways, but biotechnology can help to fight those threats, 
through innovation, investment, sustainable agriculture development and trade policies. The 
role of biotechnology in the adjustment of agriculture to new climate changes is present to 
improve resistance to biotic and abiotic factors raised by climate changes. Biotechnology for 
example can help to improve resistance to abiotic factors by transferring a gene from a salt 
tolerant plant into susceptible crops to create salt crop resistance (Roy et al., 2014), to improve 
drought tolerance in transgenic rice (Selvaraj et al., 2017), to create plants tolerant to high 
temperatures (Bita and Gerats, 2013). Also, resistance to biotic factors (pests, diseases, weeds, 
etc), can be achieved by creating transgenic plants through biotechnology. Rice and soybean 
are relevant crops that have been transgenic modified to be resistant to virus, fungi, insects and 
herbicides, to overcome the global high losses produced by these biotic factors (Yapa, 2017). 
Genetic manipulation can also be used to modify fruit maturation through metabolic routes that 
lead to ethylene synthesis and degradation, modifying the plant organ maturation. But even so, 
we also need to create plants more space efficient. But plant agriculture also contributes to 
climate change, with the increasing number of greenhouses, and to a high polluted environment 
made by the uncontrolled and unknown use of chemicals to control pests and diseases. 
Economic and agronomic research proposes that the improvement of existing agricultural 
biotechnology can reduce greenhouse gas emissions by enhancing carbon sequestration on 
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cropland, decreasing the need for cropland expansion and reducing the use of carbon intensive 
inputs like fuel, insecticides and some herbicides. 
By 2050, it is estimated that the global population will be around 9 billion. To sustain this 
population it will require food supply to double, demanding an increase of agriculture output. 
To address these future issues, genetic modifications can also be applied to produce plants for 
a high yield and seeds that are tolerant to new agriculture conditions (Searchinger et al., 2014).  
It is important for countries to invest in technology to address food security rising problems, 
and see technology as a tool for economic growth. By producing the principal grains that feed 
most of the world, biofortified rice, wheat and corn, with increased mineral and vitamin content, 
the poorest countries can also improve their low variety diet (Hefferon, 2015). Biofortified 
foods can be obtained either through the generation of transgenic plants that have additional 
biosynthetic pathways, such as vitamin A enriched “Golden Rice” or by changing the general 
physiology of the plant in such a way that is able to extract more micronutrients from the soil. 
Some successful trials have be done to prove the efficiency of biofortified crops in 
micronutrient absorption on target populations, like enriched wheat with zinc, enriched beans 
and pearl millet with iron and enriched maize and cassava with Provitamin A (Bouis and 
Saltzman, 2017). Recently, new biotechnology techniques are revolutionizing the way food 
crops can be enhanced to respond to the actual humankind needs, by editing the genome.  
TALENs (Transcription Activator-like Effector Nucleases) and CRISPR (Clustered Regulatory 
Interspaced Short Palindromic Repeats)/Cas9 systems have been proven to be effective and 
reliable techniques for genome editing. These systems are relative simple and have a high 
efficiency in human, animal, and plant cells. Many genes have been targeted for mutations by 
TALENs in plants, including rice, barley and arabidopsis. For instances, TALENs was used to 
induce in rice disease resistance against Xanthomonas oryzae pv. oryzae (Li et al., 2012). 
CRISPR-Cas 9 has been widely used due to its easy engineering. Some of the species with more 
targeted genes are Arabidopsis, rice, maize, Nicotiana benthamiana and tomato (Malzahn, 
2017). Plant immunity against DNA viruses was achieved in N. benthamiana with CRISPR-
Cas 9 (Baltes et al., 2015).  
To improve plants features, study plant gene expression and expression of foreign proteins, 
transformation with single genes is used. Nevertheless, in some situations transformation of 
plants with multiple genes is more suitable. Such as for, improving plants with multigenic traits, 
improving or changing metabolic pathways, expressing multimeric foreign proteins and 
expressing multiple enzymes involved in the synthesis of one or various compounds, such as 
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switchgrass (Panicum virgatum L.), produced for bioenergy due to high biomass production 
carrying multiple genes of interest (Ogawa et al., 2014).  
2. Plant genetic modification 
 
Since the beginning of cultivation thousands of years ago plant breeding has been performed 
by humankind. Wild species were selected based on the advantageous characteristics (Vavilov, 
1935), as flavor, size, resistance to seed or fruit drop, enhanced flavor, reduce dormancy, visual 
attractiveness, yield, resistance to abiotic and biotic factors. On the earlier 20th century Darwin’s 
theory of evolution through selection and Mendel’s laws of genetics led to modern plant 
breeding methods, where breeders/farmers use cross hybridization to combine genetic 
characteristics from different parental plants before selecting superior plants, meaning those 
with characteristics beneficial to humans, with new combinations of specific desirable traits 
among the progeny (Fu, 2015). Plant breeding can be performed using many different 
techniques, starting from the simple plant selection to the use of molecular biology techniques 
based on the genetics and chromosomes knowledge. The basic methods of classical plant 
breeding, backcrossing, inbreeding, hybrid breeding, mutation breeding and molecular-marker 
assisted selection where followed by new techniques, that allow to create further traits and to 
exchange features across species, that before were impossible. Plant breeding has been 
responsible for 50% or more of yield improvement in different crops, since 1930. In parallel 
other methods were or are being developed to interfere and specifically target plant DNA on a 
more efficient way. These methods include gene editing, ex: CRISPR-Cas9, cisgenesis, 
intragenesis, TALENs. Genetic engineering is intended to target a change in a plant gene 
sequence to effect a specific result through the use of recombinant DNA technology by using 
several approaches, ex: genetic transformation mediated by agrobacterium, agroinfiltration, 
particle bombardment and electroporation, RNA-dependent DNA methylation, 
oligonucleotide-directed mutagenesis, among others. Plant improvement programs frequently 
use a combination of molecular plant breeding and genetic engineering approaches, both 
making part of a long pathway on adapting crops to our needs.  
With the development of plant biotechnology the possibility for the introduction of just one or 
several genes in crop plants, not only from the same plant, but also from other plant species and 
from completely different organisms has evolved, and a new branch of plant biotechnology – 
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Molecular Farming, was created for genetic modified plants that produce heterologous proteins 
and chemicals. Development of techniques based on natural methods as agrobacterium-
mediated transformation or artificial methods as electroporation and particle bombardment, 
among others, gave a high contribution to plant biotechnology. 
Stable genetic transformation through electroporation for plants is a technique that had a major 
importance in the 1980s and was widely adopted (Fromm et al., 1985). Electroporation is a 
phenomenon where protoplasts are mixed with DNA in solution and subjected to a brief pulse 
of electrical current to create transient pores in the cell's membrane that allow DNA to enter 
efficiently. This allows yields of high frequency of both stable transformation and transient 
expression. Transformation by this method was developed for genetic transformation of 
monocotyledonous plants as corn (see review at Yadava et al., 2016) and to plants recalcitrant 
to Agrobacterium mediated transformation (see below).  
Gene delivery by particle bombardment or biolistic has become a widely used technique since 
the first studies by Christou (1988). This technique results when microprojectiles, usually 
tungsten or gold particles, coated with DNA, are propelled at the target cells, by acceleration. 
Microprojectile bombardment is optimized to deliver genes into the nuclear genomes of the 
plant cells. This technique may be applied to isolated cells or to apical meristems. Particle 
bombardment as well as electroporation may be limited by the regeneration capacity of the 
targeted cells or tissues (biolistic). 
Genetic transformation also uses species of bacteria that are capable of transferring genes to 
higher plant species, namely Agrobacterium tumefaciens and A. rhizogenes, both widely used. 
A. tumefaciens is a naturally occurring soil microbe well known for causing crown gall disease 
on susceptible plant species. A. rhizogenes is responsible for hairy root disease in a broad range 
of dicotyledonous plants and some gymnosperms. These two Agrobacterium species elicits 
plant cell transformation by a complex series of chemical signals between the bacterium and 
the host that result in the movement and integration of a segment of T (transfer)-DNA to the 
nuclear genome of the host plant cells. This methodology allows the transfer of some genes (T-
DNA) from an expression vector carried by A. tumefaciens into the genome of the host plant 
cells. Main advantages to use Agrobacterium to mediate transformation is the production of 
transgenic plants with single gene insertions. The soil bacterium A. rhizogenes induces the 
formation of adventitious roots by infecting the plant tissues. Hairy roots grow rapidly, 
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developing many branches without the need for in vitro exogenous plant growth regulators. 
Hairy roots culture are often used to produce secondary metabolites (Sharma et al., 2013).  
Functional analysis of transgenes and RNA silencing studies may be performed through 
agroinfiltration, a simple and effective method, involving the injection of A. tumefaciens into 
leaves or organs of a plant followed by the monitoring of transient transgene expression within 
the infiltrated tissue during the next days (Voinnet, 2001). Transgene delivery occurs through 
infiltration of A. tumefaciens carrying the transgene into the interstitial space of the mesophyll 
and then into the plant cells (Chen et al., 2013). This strategy involves the transfer of genes (T-
DNA) into the nucleus of the host plant cells and transient expression through RNA synthesis 
and further production or not of protein. The leaves infiltration process can be done either with 
a syringe or by vacuum (Bashandy et al., 2015).  
Agroinfiltration can be performed with a variety of expression vectors, including plant virus-
based vectors. Transient expression with virus-based vectors can drive higher levels of protein 
accumulation in whole plants in a faster way. While many different plant viruses have been 
modified to function as expression vectors. As an example, Tobacco mosaic virus (TMV)-based 
vectors are used due to express the highest levels of foreign protein in plants (Lindbo, 2008). 
The vectors based on virus are used according to the plant species and where the protein 
expression should happen.  
Continuous efforts must be made in plant breeding and cultivation techniques, to make plants 
production systems more efficient, sustainable and flexible. From a political and regulatory 
point of view, it’s very important that innovation carries on getting sufficient opportunities and 
that considerations about new technologies are conducted truthfully with base on scientific data.  
3. Molecular Farming 
 
Biotechnology advances of the past few years have been tremendous, and nowadays plants are 
ideal candidates to produce heterologous proteins, that are used in pharmaceutical and industrial 
sectors (Ramalingam et al., 2017). These proteins are obtained through recombinant DNA 
technology .Hind III was the first restriction endonuclease to be isolated in 1970 (Smith and 
Wilcox, 1970), and this finding led to recombinant DNA technology. In 1973 the first 
recombinant DNA experiment was published by Cohen and Boyer, twenty years after the 
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discovery of the DNA structure by Watson and Crick (Cohen et al., 1973). In this experiment 
they cut a DNA fragment from an E. coli plasmid and transferred it into another E. coli DNA 
for gene expression. Nowadays, expression is not restricted to bacteria and recombinant 
techniques have been used with yeast, algae, plants, mammalian cell culture and to produce 
transgenic animals.  
Molecular farming is described as the experimental application of biotechnology involving the 
production of proteins and chemicals by plants that are used for medical and commercial 
purposes. Molecular farming can be one of the options to produce biocompounds cheaper, safer, 
in bulk and that can be easily stored. Molecular farming makes use of distinct strategies for 
gene transfer that involve the stable genetic transformation or the transient expression of a 
nonintegrated transgene, to produce industrial enzymes, antibodies, vaccines, therapeutics, 
nutraceuticals and other pharmaceutical proteins (Moshelion and Altman, 2015). 
Human insulin was the first recombinant protein approved by the United States Food and Drug 
Administration (FDA) to be used as a drug in 1982, after that the request for recombinant 
proteins, especially pharmaceutical proteins increased (Ma and Wang, 2012). A human growth 
hormone was the first plant-derived recombinant pharmaceutical protein to be produced in 1986 
in transgenic tobacco (Barta et al., 1986). The first plant-derived antibody was reported in 1989 
(Hiatt et al., 1989). In 1992, the first plant-derived vaccine, hepatitis B virus surface antigen, 
was expressed in transgenic tobacco (Mason  et al., 1992). The first plant-derived recombinant 
protein for commercial purposes was produced in 1997, avidin and egg protein was produced 
from maize (Hood et al., 1997). 
Some of the advantages of using plants are their low cost of production, considering that plant 
growth, transport and post-harvest are relatively economical, rapid scalability, absence of 
human pathogens reducing the risk of contamination, high biomass production and ability to 
produce high yield proteins accurately. One of the problems of using plants is the long timescale 
of production compared with microorganism or animal cell cultures.  
For protein production in plants, theoretically any type of plant can be transformed, however it 
is wiser to use well studied and characterized plants for efficient protein production. Tobacco 
may be the ideal candidate to high-efficiency protein production in green tissue as it is a leafy 
plant that has a high capacity to produce biomass (Fischer et al., 2004). In addition, maize, rice 
and wheat also have been used for recombinant protein production.  
 
8 
On section 5, it will be described biotechnology techniques that can be used during the process 
to obtain recombinant proteins from plants, and also to obtain modified plants needed to face 
the future.  
4. Bio-safety 
 
The development of genetically engineered plants brings a lot of benefits but with it also 
potential serious risks. Those risks are associated with the contact of genetic modified crops 
with wild species or other organisms, like bacteria and virus; the contact of crops resistant to 
pests and diseases with wild species, allows the opportunity for pests and diseases evolution 
leading to resistance. Thus the introduction of genetically modified crops raised public concern, 
in part due to lack of communication between authorities dealing with researchers, and also for 
the bio-safety and trade, leading to a delay in growth of molecular farming (Rastogi, 2013). 
Work has been done to reduce environmental exposure to transgenics, by conducting controlled 
trials where environmental risk assessments are performed in order to follow the regulations 
and national laws for GMOs (Roberts et al., 2014), but we are still far away from a common 
solution to solve all the problems around regulations of molecular farming products. 
It is very difficult to assess the long-term impact of molecular farming on the environment. One 
of the important concerns is the contamination of the food chain with pharmaceuticals plants. 
This can happen, just by using the same equipment for harvesting and processing of transgenic 
and food crops without proper decontamination and by growing food crops in the same field 
where transgenic crops where implemented previously without proper decontamination. To 
prevent this from happening, strict regulation needs to be implemented, including geographical 
restrictions on the location of transgenic crops, and harvesting and processing of these modified 
crops with designated equipment and proper decontamination if using the same equipment for 
food crops. The labeling of genetically modified products is essential, to inform and allow the 
customer to select according to their preferences.  
The risks to human health by ingesting new proteins that didn’t had a complete study on their 
impact at long-term consumption on the development of allergies or diseases brings a lot of 
public concern. The regulation of transgenic crops is a real challenge for regulatory agencies, 
each molecular product and each host system are a case that needs to be analyzed separately. 
The European Parliament and the Council of the European Union allowed the presence of 0.5% 
of transgenic material in non-transgenic food, in cases where the presence of transgenic material 
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is inevitable and the benefits are above the negative effects (EU, 2003). They are several ways 
of controlling gene flow among GMO’s  to prevent contamination of other species, mainly 
maternal inheritance, seed sterility and male sterility. By using sterile male traits and chloroplast 
transformation of plants, contamination of food crops can be prevented (Adem et al., 2017). 
The chloroplast genome is maternally inherited, so the chances for transgene spread through 
pollen are controlled. Even so, they are no tactic that can be applied to all the crops, and a 
combination of strategies for controlling gene flow seems more effective. 
5. Molecular Biology techniques 
 
Some of the basic molecular biology techniques used to promote biotechnology related to 
molecular farming will be described in this report as DNA extraction, PCR, colony PCR, 
agarose gel electrophoresis, transformation, protein expression, SDS-PAGE and Western Blot. 
These techniques allow to study better ways to improve plants growth and production, helping 
agriculture meet future challenges. These techniques were applied by me in several 
experimental studies performed as a Research Technician/Research Assistant in the University 
of Leicester with bacteria and animal cells. 
5.1. Standard stock and buffers 
 
This section describes general protocols of the most common methodologies used in molecular 
biology. Table 1 describes, in detail, stocks and solutions used in the following molecular 
biology protocols. 
 
Table 1 - Standard stocks and buffers. 
Stocks and Buffers Reagents   Reference 
PBS(1x) 
7.35 g NaCl 
2.35 g Na2HPO4 
1.3 g NaH2PO4.2H2O 
1L dH20 
pH adjusted to 7.1 
(Dulbecco and Vogt, 
1954) 
TAE buffer (50x) 
 
242 g tris base 
57.1 ml glacial acetic acid 
37.2 g Na2EDTA.2H2O 
1L dH20 
pH adjusted to 8.5 
(Ogden and Adams, 1987) 
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Coating solution 
 
0.606 g Na2CO3 
1.2 g NaHCO3 
200 ml dH2O 
 pH adjusted to 9.6  
(Engvall and Perlmann, 
1971) 
Blocking solution 
 
0.5 g of milk  
10 ml of 1x PBS 
(Engvall and Perlmann, 
1971) 
Luria-Bertani broth 
 
4 g tryptone 
2 g yeast extract 
2 g NaCl 
400 ml dH2O  
 
(Luria and Burrous, 1957) 
 
Luria-agar 
 
Same as Luria-Bertani broth 
with addition of 1.5%(w/v) of 
agar 
(Luria and Burrous, 1957) 
SOC medium 
 
SOB medium: 
4 g tryptone 
1 g yeast extract 
0.1 g NaCl 
200 ml dH2O 
 
Plus: 
50 μl 2M MgCl2 
200 μl 1M glucose Filter-
sterilized through 0.2 μM 
acrodisc syringe filter and added 
to 10 ml of SOB medium 
immediately before use. 
(Sambrook et al., 1989) 
 
All media are autoclaved at 121oC, 15 psi for 20 minutes.  
 
5.2. DNA extraction 
 
The genomic DNA in plants is frequently larger than in animals (Bennett and Leitch, 2005) and 
compounds found in plant cells are not present in animal cells. These differences will dictate 
the different extraction methods, which influence the yield and purity of DNA. To extract 
genomic DNA from any prokaryotic or eukaryotic cell three central steps are needed: disruption 
of cell walls/membranes, separation of DNA from all other components (cell wall debris and 
metabolic substances) and maintain the integrity of DNA during the extraction. The extraction 
of genomic DNA is normally performed with a special extraction buffer and is purified by a 
phenol/chloroform extraction followed by isopropanol and/or ethanol precipitation (Fredricks 
and Relman, 1998), although other methodologies are available. Amounts of RNA and protein 
contaminants differ considerably between species, and these variations will dictate the selection 
and development of the cell lysis appropriate for the species that is being studied.  
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In the past few decades, scientists have developed numerous protocols and procedures for the 
extraction of DNA from different plant species, that are different based on the purpose of the 
isolation. Some of the most common procedures were described by Murray and Thompson, 
(1980), Doyle and Doyle (1987) and Rogers and Bendich (1988). However, there is not a 
universal protocol that can be used for all plant varieties. It can be difficult to obtain high quality 
DNA extractions from plants, being one of the key steps the preparation of tissues for 
extraction. Usually, liquid nitrogen is used to flash freeze followed by grinding the frozen tissue 
with a mortar and pestle. Some plant species can contain a lot of contaminants as 
polysaccharides, polyphenols and tannins that can inhibit some components of the solutions 
used during the extraction. During the initial centrifugation steps, the cell wall and other larger 
structures are removed, however polyphenols can still be present. DNA analysis by PCR can 
be affected by the variation in the lysis efficiency and DNA purity. To obtain the desired DNA 
quality, an existing protocol needs to be adapted, combined or developed. For example, to 
improve the DNA quality from strawberry leaves (Fragaria ananassa L.), Nunes et al. (2011) 
combined lyophilization and polivinilpirrolidone (PVP) that helped on the quality and amount 
of genomic DNA extracted from young leaves. The typical protocols for DNA extraction are 
not suitable for mango tree (Mangifera indica L.) due to the high content of secondary 
metabolites that can interfere with analytical applications, so Uddin et al. (2014) removed the 
undesirable polysaccharides, polyphenols and secondary metabolites from genomic DNA by 
modifying a traditional cetyl trimethyl ammonium bromide (CTAB) method by adding 0.4 M 
glucose. 
Due to my long experience with plasmid DNA, below I will describe a protocol for DNA 
isolation based in extraction of plasmid DNA from bacteria. To extract plasmid DNA the right 
lysis method plays an important role to assure the separation from genomic DNA. As an 
example two commercial available kits NucleoSpin Plasmid (Macherey-Nagel, UK) and 
QIAprep Spin Miniprep (Qiagen, UK) are used. Both kits use the alkaline lysis method of 
Birnboim and Doly (1979).  
To perform a DNA extraction of plasmid DNA, all the centrifugation steps should be performed 
at room temperature. From an overnight culture of Escherichia coli growing in LB plus required 
antibiotic, 10 ml are used to do DNA extraction. The culture is transferred into eppendorf tubes 
and centrifuged for 30 seconds. The cell pellets are ressuspended in the buffer provided by the 
kit containing RNase A (to a final concentration of 0.1 mg/ml and 0.4 mg/ml for the QIAprep 
Spin Miniprep kit and NucleoSpin® Plasmid kit, respectively). Sodium dodecyl 
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sulphate/alkaline lysis buffer provided by the kit is added to the tubes and carefully mixed. The 
tubes are incubated for 5 minutes at room temperature, until a clear and viscous lysate is visible. 
Guanidine hydrochloride buffer is added and incubate for 10 minutes to neutralize the lysates 
and allow the precipitation of denatured proteins, cell debris and other resulting products from 
lysis. The tubes are centrifuged for 10 minutes. The supernatant is transferred to the silica-
membrane spin column and centrifuged for 1 minute, to allow for the DNA to bind to the 
column. The column is washed with an “ethanolic” solution, centrifuged for 1 minute, followed 
by another centrifugation for 1 minute to allow the membrane to dry. The DNA is eluted, by 
adding 50 μl of Tris-HCl (pH 8.5) buffer to the column and incubated at room temperature for 
1 minute. The column is centrifuged for 1 minute and the plasmid DNA collected into a clean 
and sterile eppendorf tube.  
 
5.3. Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR) is used in agricultural biotechnology at different stages of 
product development. PCR allows the cloning of a definite gene and the specific detection of a 
DNA fragment from a complex range of DNA and its subsequent amplification. During product 
development PCR can be used for seed quality control, gene discovery, screening and 
characterization. One of the main applications for PCR currently in the agricultural sector is to 
verify the presence or absence of genetically modified (GM) material in a product and/or to 
quantify the amount of GM material present in that product. Rott et al. developed in 2004 a 
method to detect the presence of genetic modified soybean in sausages made from soybean 
Roundup Ready®. Also, Ma et al. developed the restriction site-anchored single-primer PCR 
method to obtain the unknown flanking sequences of transgene sequences in the maize 
transgenic plants (2014).  
To perform a PCR reaction the following reagents are needed: template DNA, primers, 
nucleotides (adenine, thymine, cytosine and guanine), and DNA polymerase. The DNA 
polymerase links the nucleotides together to synthesize new DNA sequences that form the PCR 
product. 
The primers detect the exact part of the sequence that we are looking for to amplify. DNA 
amplification occurs in three steps: denaturation, annealing and elongation. The thermal cycler 
machine lowers and raises the temperature of the block in precise, discrete and pre-programmed 
steps. The amplified copies can be detected by gel electrophoresis by their distinct size, 
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separated under electrical current. There are no significant differences between using a DNA 
template from animal or plants or bacteria. The PCR reagents may need to be adapted according 
to the segment size and DNA nucleotide composition that we want to amplify, as well as the 
cycling conditions. For the colony PCR an additional step is necessary to break the membrane 
from the bacteria so the DNA is released.  
 
The PCR mixes are prepared on ice in a 50 μl reaction, using the following reagents:  
 
- 5 μl 10x NH4 reaction buffer: 160 mM (NH4)2SO4, 670 mM Tris-HCl (pH 8.8 at 25°C), 
0.1% (v/v) Tween-20 (Bioline).  
- 1.5 μl of 50 mM MgCl2 solution (Bioline).  
- 1 μl deoxyribonucleotides triphosphate mix (dNTPs): 10 mM of each dATP, dCTP, 
dGTP, dTTP (Bioline). This mixture is prepared by adding 10 μl of each dNTP (100 
mM) to 60 μl ultra nanopure H2O. The solution is mixed, aliquoted and stored at -20°C.  
- 25 pmol of each primer (forward and reverse). 
- Up to 100 ng of DNA is used as a template. For the negative control, DNA is replaced 
by ultra nanopure H2O.  
- 1 μl (5 units) of thermostable BIOTAQTM DNA polymerase (Bioline).  
- Ultra Nanopure H2O, up to a final volume of 50 μl. 
 
The PCR mixtures are centrifuged for 10 seconds and placed in a T-Gradient Thermal Cycler 
(Biometra, Germany). The thermal cycling program is performed using the following 
parameters: 
 
Table 2 - Standard conditions for PCR. 
DNA template 
Step Temperature Time  
Initial denaturation 95°C 1 minute  
Denaturation 94°C 30 seconds  
30 cycles Annealing 65°C 30 seconds 
Elongation 72°C 2 minutes 
Elongation hold 72°C 10 minutes  
            The PCR products are analyzed by agarose gel electrophoresis (section 5.5). 
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5.4. Colony PCR 
 
Colony PCR is a method to screen positive clones from ligation reactions, by determining the 
presence or absence of insert DNA in plasmid constructs. The PCR mix is prepared on ice in a 
15 μl reaction, using the following reagents:  
 
- Small amount of one (1) colony. In the negative control add water.  
- 5 μl ultra Nanopure H2O. 
 
To each PCR tube containing nanopure water a small amount of one colony is added. To do 
this, a fine yellow pipette tip attached to the pipette lightly touches the side of one colony, the 
mixture is mixed by pipetting up and down. The mixture is placed in a T-Gradient Thermal 
Cycler (Biometra, Germany) for 10 minutes at 95°C. After that the following reagents are 
added: 
 
- 1.5 μl 10x NH4 reaction buffer: 160 mM (NH4)2SO4, 670 mM Tris-HCl (pH 8.8 at 
25°C), 0.1% (v/v) Tween-20 (Bioline).  
- 0.45 μl of 50 mM MgCl2 solution (Bioline).  
- 0.3 μl deoxyribonucleotides triphosphate mix (dNTPs): 10 mM of each dATP, dCTP, 
dGTP, dTTP (Bioline). This mixture is prepared by adding 10 μl of each dNTP (100 
mM) to 60 μl ultra nanopure H2O. The solution is mixed, aliquoted and stored at -20°C.  
- 7.5 pmol of each primer (forward and reverse). 
- 0.3 μl (5 units) of thermostable BiotaqTM DNA polymerase (Bioline).  
- Ultra Nanopure H2O, up to a final volume of 15 μl. 
 
The PCR mixtures are centrifuged for 10 seconds and placed in a T-Gradient Thermal Cycler 
(Biometra, Germany). The thermal cycling program described in Table 2 is used and the 
products by agarose gel electrophoresis are analyzed (section 5.5). 
5.5. Agarose gel electrophoresis 
 
Electrophoresis is the most common method used to separate DNA fragments of different sizes. 
For the agarose gel electrophoresis, the size of the fragment that we are looking at is important 
to determine the percentage of agarose in the gel. Higher percentage of agarose increases 
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resolution of smaller bands, equally the lower the agarose percentage better resolution and 
separation of higher molecular-weight bands. 
Considering for instance, that the size of the DNA fragments that we are looking for are 
approximately 1.5 Kb and 2.2 Kb, the PCR products should be run on a 0.9% (w/v) agarose gel 
to allow separation of fragments ranging from 0.5-7 Kb (as an example). For the gels 
preparation: 0.9 g of agarose (Bioline) is added to 100 ml of 1x TAE buffer pH 7.7 (from stock 
solution 50x TAE buffer). The mixture is melted in a microwave for a few minutes and left to 
cool down, ethidium bromide is added to a final concentration of 0.2 μg/ml. The gel is poured 
into a sealed tray with a well-forming comb and left to set. Next, the gel is transferred to the 
electrophoresis tank containing 1x TAE buffer, the comb is removed carefully and the samples 
are loaded. One of the wells is loaded with 1 Kb DNA ladder (MBI Fermentas, UK), to allow 
determining the size of the DNA fragments of interest. The DNA samples are diluted in 1x 
DNA loading dye (6x DNA loading dye - Fermentas, UK) and loaded into the gel wells.  
Electrophoresis is performed at 70 V, for approximately 20 to 30 minutes and the gel is 
visualized under a UV transilluminator. The image is captured, using for example an 
ImageQuant 100 (GE Healthcare) imaging system with the IQuant Capture 100 software (GE 
Healthcare). 
 
5.6. Purification of PCR products 
 
For the success of cloning it is important to purify the PCR products, to ensure the removal of 
short primers, dNTPs, enzymes, salts and short-failed PCR products that could interfere with 
the cloning steps. The silica membrane adsorbs the DNA when exposed to high concentration 
of salt, and allows the contaminants to pass through the column. The impurities are washed 
away, and the cleaned DNA is eluted with Tris buffer or water (www.qiagen.com). 
Per each 1 volume of PCR product, 5 volumes of binding buffer is added and mixed. The 
mixture is transferred to a silica-membrane spin column and centrifuged for 30 seconds at 
17,900 g, to allow the DNA to bind to the column. After that, an “ethanolic” buffer is added to 
the membrane to wash all the unwanted PCR products and impurities, centrifuged for 1 minute 
at the same speed, and spun again to dry out the membrane. Tris-HCl buffer (pH 8.5) is added 
to the column and left to incubate for 1 minute at room temperature, the column is spun again 
for 1 minute. The pellet containing the purified PCR product is collected into a clean and sterile 
eppendorf tube. 
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5.7. Cloning of targeted gene sequences into an expression vector 
 
To clone a specific gene we need to take into account that the process differs from species to 
species and from gene to gene. The choice of an appropriate vector is an initial extremely 
important step. For easy manipulation, the vectors should be small molecules, capable of 
prolific replication in a living cell. They also should have restriction sites so the DNA that is to 
be cloned can be inserted.  
For the cloning of targeted gene sequences the use of In-FusionTM Dry-Down PCR Cloning Kit 
is described as an example. This kit allows joining multiple pieces of DNA that have 15 base 
pairs of homology at their linear ends. This kit produces accurate constructs with inserts in 
desired orientation rapidly (www.clontech.com). The manufacturer’s instructions were 
followed for the ligation reactions. The lyophilised reaction mixtures in a sealed 8-well strip 
are supplied with the kit. The purified PCR products are combined with the linearized vector at 
a molar ratio 2:1 in a final volume of 10 μl in ultra nanopure H2O and the mixture is transferred 
to the reaction tubes supplied. For the cloning procedure, the tubes are incubated for 30 minutes 
at room temperature. After that, the tubes are transferred to ice and used in the cloning reactions 
in transformation of chemically competent cells (section 5.8).  
 
5.8. Heat-pulse transformation of chemically competent bacterial cells- 
Transformation into BL21-Gold (DE3) pLysS competent cells  
 
BL21-Gold (DE3) pLysS competent cell are an E. coli strain with a high-performance 
transformation efficiency promoting high levels of protein expression.  
The bacterial transformation protocol recommended by the manufacturer Stratagene is 
described below. The competent cells are thawed on ice, mixed gently and aliquoted into 100 
μl pre-chilled 14 ml falcon polypropylene round-bottom tubes (BD, UK). An additional tube is 
prepared with 100 μl to use as a transformation control. Approximately 50 ng (1-2 μl) of cloning 
reaction is added to the aliquots and 1 μl of pUC18 control plasmid to the transformation control 
tube. The tubes are swirled gently and placed on ice for 30 minutes. Each reaction is heat-pulse 
for 20 seconds in a 42°C water bath, followed by 2 minutes incubation on ice. Afterwards, 900 
μl of SOC previously warmed at 42°C is added to the reactions. The tubes are incubated at 37°C 
for 1 hour on a shaker set at 220 rpm. The transformation reactions are plated onto LA plates 
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containing ampicillin and incubated overnight at 37°C. The following day randomly colonies 
are selected, and run through colony PCR (see section 5.4) and placed to growth on a new LA 
plate containing the plasmid encoded antibiotic resistance and incubated overnight at 37°C. 
Lyophilized and sent for sequencing the selected transformants. 
 
5.9. Small scale protein expression 
 
On average plant proteins are larger than bacterial proteins (Tiessen et al., 2012). 
Heterologous expression is when a protein is produced in a different organism than the natural 
one, often to enable large-scale production. The most common system used for heterologous 
protein production is E. coli due to its simplicity, low cost, compatibly and fast growth rate 
(Frommer and Ninnemann, 1995). This method allows the biochemical and biophysical 
analysis of plant protein expression and purification through microorganisms. Bacteria, yeast, 
insect cells and Xenopus laevis are the systems used for recombinant plant protein production 
(Yesilirmak and Zehra, 2009). Recombinant plants proteins are used in industrial purposes, like 
cellulases, for other biomedical purposes like frutalin known by the anti-tumor properties 
present in Artocarpus incisa L. (breadfruit) and produced in E. coli and Pichia pastoris  
(Oliveira et al., 2014) and synthesis of a peptide against diabetes from ginseng (Yan et al., 
2003) in Pichia pastoris.  
The method of heterologous protein production explained below is based on the production of 
recombinant proteins in prokaryotic cells. 
E. coli carrying a recombinant expression vector with a specific gene sequence are inoculated 
into 10 ml of LB with antibiotic, with 220 rpm agitation at 37°C, overnight. The following day, 
1 ml of overnight growing culture is added into new 10 ml LB with antibiotic and incubated at 
37°C, with 220 rpm agitation, until the culture reached an OD600 of approximately 0.5-0.6. 1 
mM filtered-sterilized IPTG (Melford laboratories, UK) is added and incubated until the culture 
reached an OD600 of approximately 1.5-1.6. The cells are collected in a PK131R Refrigerated 
Centrifuge (ALC International), at 2,324 x g for 15 minutes, at 4oC. The pellet is ressuspended 
in 250 μl ice cold 1 x PBS and transferred to a clean and sterile eppendorf tube. To produce a 
crude cell extract containing the protein of interest, the cells are sonicated with a small sonicator 
probe (Soniprep). To prevent overheating from the sonication process, the tubes are kept all the 
time in a glass beaker filled with ice. During the sonication process intervals of 1 minute is 
made, and 5 seconds of pulse with amplitude of 6 microns is applied, followed by a “cool down” 
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period of 55 seconds. This step is performed 5-6 times or until the extract became clearer and 
less viscous. The tubes are centrifuged at 15,115 x g in a bench-top centrifuge at 4oC for 10 
minutes. The supernatant is collected into a clean and sterile eppendorf tube. 
 
5.10. SDS polyacrylamide gel electrophoresis (SDS-PAGE)  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate 
components of a protein mixture according to their molecular weight, based on their length. 
Being the most common method used to obtain high resolution analytical separation of proteins 
mixtures. An initial denaturation of the proteins mixture with an anionic detergent that binds to 
the proteins, charges the proteins negatively in proportion with their molecular weight. After 
this, the proteins are separated through a porous acrylamide gel by electrophoresis based on 
their molecular weight. This method has been used since the early 1970s, and works in 
applications that do not require retention of native features of protein structure or function 
(Laemmli, 1970). This method has been widely used to study proteins from organisms of all 
kingdoms since its discovery. As an example of its use for plant protein analysis, Chernyshenko 
et al., in 2016 used this method to estimate the protein composition of roots and leaves of 
Ophioglossum vulgatum.The protocol described in this section needs to be adapted to the type 
and size of the proteins that we are looking for.  
A 5% (w/v) stacking gel and 12% (w/v) resolving gel are used.  
 
5.10.1. Gels preparation 
 
For the casting frames, two glass plates are evenly aligned and clamped in the casting frames 
on the casting stands that are sealed by the casting gaskets on the bottom. In a falcon tube 15 
ml of 12% (w/v) resolving gel is prepared (Table 3), by mix thoroughly and pipette into de gap 
between the glass plates, leaving up to 1 cm below the level of the comb teeth. The gap is filled 
with dH2O to prevent dehydration and the gel left to jellify for 30-45 minutes.  
 
 
 
 
  
19 
Table 3 - Solutions for preparation of 12% (w/v) resolving gels and 5% (w/v) stacking gels for SDS-PAGE. 
Solution Resolving gel 
12% 
Stacking gel 
5% 
30% (w/v) acrylamide 6.0 ml 830 µl 
1.5 M Tris-HCl , pH 8.8 3.8 ml - 
1.0 M Tris-HCl , pH 6.8 - 630 µl 
10% (w/v) SDS 150 µl 50 µl 
10% (w/v) ammonium persulfate  150 µl 50 µl 
TEMED 6 µl 5 µl 
Nanopure H20 4.9 ml 3.4 ml 
Final volume ≈15 ml ≈5 ml 
 
In the meantime, 1x running buffer is prepared, by adding 100 ml of 10x Tris-glycine-SDS 
(TGS) electrophoresis grade buffer (National Diagnostics) into 1L of dH2O. The water is 
discarded and the excess absorbed with filter paper. 5 ml of 5% (w/v) stacking gel (Table 3) is 
prepared, mixed thoroughly and pipetted into de gap between the glass plates. The well-forming 
comb without trapping air under the teeth is carefully insert, before polymerization begged. The 
gel is left to polymerize for 20-30 minutes. If the gels are not used on the same day, they are 
stored in 1x TGS at 4°C.  
 
5.10.2. Sample preparation 
 
To treat the samples, a reducing buffer is used in the presence of heat. The samples are mixed 
with 4x NuPAGE® LDS (lithium dodecyl sulphate) to a final concentration of 1x. A beaker is 
placed to boil with dH2O on a hot plate. The lid of the tube samples is punctured with a needle 
to release the pressure inside the tube caused by temperature differential during boiling. After 
the beaker is boiling the samples are placed on a floating rack and transferred to the boiling 
water for 5 minutes.  
 
5.10.3. Electrophoresis 
 
The molding combs are gently remove after polymerization. The glass plates are removed from 
the casting frame and the gels placed into the electrophoresis tank, half-filled with 1x TGS. The 
protein marker (e.g.: Precision plus protein standard – all blue; Bio-Rad) is added to one well 
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alongside the samples and the electrophoresis chamber is filled with 1x TGS. The anodes of the 
Mini-PROTEAN 3 cell (Bio-Rad) tank are connected. The voltage is set at 40 mA and the gels 
run until the protein marker almost reaches the foot of the glass plates. After the run finished, 
the gel cassettes are gently removed and the gels carefully transferred into a large Petri dish. 
The gel is carefully washed with dH2O and Coomassie blue staining solution (prepared by 
adding 1 part ethanol to 9 parts Protoblue safe – colloidal Coomassie blue G-250 stain from 
National Diagnostics) is added to the Petri dish and left to incubate overnight on a rocker plate. 
The following day, the gel is washed in dH2O and analyzed. Alternatively, the gels are 
transblotted for later immunodetection (see section 5.11). 
 
5.11. Western Blot 
 
Western blot is an important technique widely used in cell and molecular biology to identify a 
specific protein in a sample mixture of proteins, that was introduced by Towbin et al., 1979. 
This technique allows the identification of specific proteins from a complex mixture of proteins 
extracted from cells. Western blot can be divided into three parts: protein separation by size, 
transfer to a solid support and protein target marking with specific primary and secondary 
antibodies to identification. Western blot has been widely used as an analytical technique for 
studies of plant proteins, e.g. the detection of the presence of glutamine synthetase polypeptides 
on leaf extracts of tobacco (Nicotiana tabacum L.) (Carvalho et al., 1992), the identification 
and validation of reference rice proteins (Li et al., 2011) or to confirm the presence of 
recombinant CCL21 protein, a chemokine that can be used for anti-metastatic of cancer cell 
lines in Solanum lycopersicum (Beihaghi et al., 2018). In the protocol described below some 
changes may be necessary considering the type of proteins that we are looking for. The 
antibodies should be specific for the protein that we are looking; incubation periods, reagents 
and gel running time may need to be adapted.  
 
5.11.1. Transferring the protein from gel to the membrane 
 
After protein samples electrophoresis through a 12% (w/v) SDS-PAGE (see section 5.10), the 
sandwich transfer is assembled. The gels are placed in 1x transfer buffer (5.9 g Tris, 2.9 g 
glycine, 200 ml methanol, 3 ml 10% (w/v) SDS, 800 ml distilled H2O, pH 8.3) for 10 minutes. 
For the sandwich assemble, a foam pad is placed on one side of the cassette (negative side) and 
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one sheet of filter paper (Bio-Rad) on top of the pad, the gel is placed on top of the filter paper 
followed by nitrocellulose membrane (Amersham) placed on the positive side. The second sheet 
of filter paper is placed on top of the stack, followed by a second foam pad on top and the 
cassette holder is closed, making sure that no bubbles are trapped in the sandwich. The cassettes 
are transferred to the mini trans-blot tank (Bio-Rad) filled with ice-cold transfer buffer and an 
ice block is placed into the tank. The system is turned on for approximately 1 hour at 250 mA. 
After the transfer is complete, the nitrocellulose membrane is carefully removed with forceps. 
The membrane is blocked overnight with 5% (w/v) skimmed milk in PBS at 4 °C. 
 
5.11.2. Immunodetection 
 
The following day, the membrane is washed 3 times for 10 minutes with 0.05% (v/v) Tween 
20 (PBS-T). The membrane is incubated with primary monoclonal antibody [1:1000 dilution 
in PBS-T plus 2% (w/v) skimmed milk], at room temperature and placed on a shaker for 90 
minutes. After that, the membrane is washed four times for 10 minutes with PBS-T (10 minutes 
each wash), and incubated with the secondary antibody, goat anti-mouse IgG (Sigma) alkaline 
phosphatase conjugate [1:2000 dilution in PBS-T plus 2% (w/v) skimmed milk], at room 
temperature and placed on the shaker for 1 hour. Lastly, the membrane is washed 4 times for 
10 minutes with PBS-T, and incubated with approximately 5 ml of BCIP/NBT liquid substrate 
system (Sigma) until the bands are visible and the detection of the antibody complex possible.  
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III – Curriculum vitae 
On this chapter, I will present my academic qualifications, focusing on my professional career, 
present my publications and explain the relevance of my experience to obtain the 
“Hortofruticultura” Master’s degree.  
7. Academic pathway  
 
I attended the 1st cycle of basic education from 1987 to 1991 in Escola E.B. 1 nº 1 de Tavira, 
and the 2nd cycle of basic education from 1991 to 1997, finishing the 3º cycle of basic education 
in 1999 with a final score of 15 out of 20. The internship was done on the final year of the 
degree in Viveiro Florestal do Algarve, Lda under the supervision of Prof. José Monteiro from 
Universidade do Algarve, with a final score of 16 out of 20, with the title “Actividade 
viveirística de espécies de jardim no Algarve. Germinação de sementes de Ceratonia siliqua L. 
e Olea europaea var. sylvestris.” 
I concluded the degree in Engenharia Agronómica – Ramo Hortofruticultura in 2005 at 
Universidade do Algarve (UALG) with a final score of 13 out of 20. In 2005 I conclude the 
Postgraduate course “Greenkeepers” with a final score of 13 out of 20.  
8. Professional career 
 
8.1.  From April 2017 until present –Syngenta Flowers 
 
I started working at Syngenta Flowers on the 3rd of April of 2017 as a Senior Grower and 
Quality Management Designate. Syngenta Flowers is dedicated to the breeding of pioneering 
flower varieties that offer outstanding performance in the professional greenhouse, at retail, in 
landscape and in the home garden. In addition to the vast experience in plant genetics, it 
supports industry professionals through world-class customer service, in-depth cultural 
information, flexible and exciting marketing programs, and a deep understanding of plants from 
many points of view. 
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8.1.1. Main activities and responsibilities  
 
Lead and take part of the coordination and supervision of cultivation activities of all flower 
crops in the execution of crop production protocols within the assigned location such that final 
results meet the client specifications whilst ensuring knowledge transfer to local teams to build 
future capabilities. Assist the Head Grower in training and supervision of both permanent and 
temporary workers. Participate in the Quality Management system; write procedures/ work 
instructions / forms; participate in yearly review of documents. Utilize keen observation skills 
to monitor plant growth & nutritional status. Observe that all cultural activities happen in agreed 
deadlines.  
8.1.2. Practical skills gained during this work 
 
- Irrigation/Fertigation - preparation of fertilizer stock solution for all Flowers greenhouses.  
- Climate control (through S-Monitor environmental control system, adjusting set points based 
on crop assessment and its phenological state; acting upon alarms provided by this system). 
- Crop Protection (implementation of chemical or biological measures; taking part in chemical 
application; continuous monitoring of crop phyto conditions). 
- Compliance with company Phytosanitary standards. Compliance with country legislation. 
- Sampling (diseases and nutritional). 
- Monitoring, calibration of equipment’s (EC/pH meters, probes, injectors, scales).  
- Keeping accurate and required records on crop production activities (including 
legal/regulatory requirements and global standards). 
- Work across boundaries – capable of replacement of department’s crucial functions during 
colleague’s absences. 
8.2.  From September 2016 until March 2017 – Universidade do Algarve 
 
The main goal of this work was to clone a fragment of each callose synthase and xylulose 
transglucosylase genes from Citrus sinensis (L.) Osbeck cv. Valencia late and Citrus 
clementina hort. ex Tanaka cv. Fina to further proceed to a qPCR gene expression analysis of 
these genes. I worked as a research technician on this project under the supervision of Prof. 
Natália Marques. 
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8.2.1. Main activities and responsibilities  
 
- Citrus and Thymus albicans RNA extraction.  
- Immunocapture/RT-PCR. 
- Primer design. 
- Amplification of gene sequences by PCR. 
- Reverse transcription-polymerase chain reaction. 
- cDNA synthesis.  
- DNA quality assessment by spectrophotometry. 
- Preparation of competent cells.  
- Transformation of E. coli. 
- Cloning of the sequences obtained into pGEM T-easy vector. 
- To identify and analyse gene expression of cal S, cal S7 and xyl glu B. 
8.2.2. Practical skills gained during this work 
 
Knowledge about all the procedures of molecular biology related to the cloning procedure, as 
described in section 8.2.1. 
 
8.3. From March 2014 until September 2016 – University of Leicester 
 
I worked as a Research Assistant/Lab manager for a project funded by Kay Kendall Leukaemia 
Fund (KKLF), under the supervision of Professor Salvador Macip and Professor Martin Dyer. 
The project aim was to discover a drug or drugs combinations to treat patients with CLL 
(Chronic lymphocytic leukemia) and HCL (Hairy cell leukemia) leukemia types, based on 
animal models.  
8.3.1. Main activities and responsibilities  
 
- To prepare and organise the laboratory to meet the requirements of the research agenda.  
Ensuring that the work environment is maintained to the standard required to deliver the 
appropriate level of service to all those who use the facilities and adhering to the relevant 
COSHH regulations and safety standards affecting self and others at all times. 
- Manage the cell bank and the DNA bank for the research group and perform key experiments 
(such as FACS, cell cultures, etc.) for the lab projects, as discussed with the line manager.   
- Coordinate with other labs working on the same project. 
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- Responsible for the maintenance and organisation of the breeding colonies of mice for 
different projects ongoing in the lab (including xenografts, transgenic and ageing models). 
- Operate a range of specialist equipment, providing instruction to others as required. 
- To procure appropriate stock levels of lab consumables etc. to ensure co-workers can carry 
out their work without interruption, ensuring effective use of budgets within the financial 
constraints of the project 
- Analyse and interpret research data and to present findings accurately. 
- Attend group meetings in order to ensure up to date knowledge of the work of the research 
group and present own experimental data, as required.  
- Liaise with other groups working on the same projects. 
- Clarify work requirements with line manager as required. 
- Order supplies and equipment to meet the requirements of the research to ensure stock levels 
are maintained. 
- Plan own workload to ensure that requirements of the project are met. 
- Perform activities to appropriate time and quality requirements. 
8.3.2. Practical skills gained during this work 
 
- Protein manipulation techniques including, protein expression, extraction and purification 
using the AKTA system, SDS gels, Western blotting and ELISA. 
- Tissue culture of human cell lines and human primary cells. 
- DNA manipulation, including PCR, transformation and DNA extraction. 
- Flow cytometry (BD FACSCalibur and BD Canto II), full understanding of the technology 
with appropriate training for samples preparation; machine operation and data analysis. 
- Full understanding of confidentiality and intellectual property protection considering that 
my role involved handling of commercially sensitive information. 
- Training and supervision of students in key laboratory techniques. 
- Maintaining laboratory equipment and organise repairs/servicing as required. 
- Maintaining the equipment and facilities within the research laboratory.  
- Maintaining breeding colonies of mice for the different research projects. 
- Managing the cell bank and the DNA bank. 
- Planning and delivering tasks to an agreed schedule. 
- Training undergraduate, postgraduate students and visiting workers in key laboratory 
techniques and use of equipment.  
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8.4.  From April 2010 until February 2014 – University of Leicester 
 
The team from PNEUMOPEP (previous work – please see below) was awarded funding 
through the Seeding Drug Discovery initiative to identify new small molecules and through a 
programme of medicinal chemistry, combined with in vitro and in vivo testing, to identify lead 
compounds with appropriate efficacy, pharmacokinetics and toxicology. I worked on this 
project, called SDDI, as a Research Technician, under the supervision of Dr Rana Lonnen and 
Professor Peter Andrew. The aim was to give such molecules would reduce the number of 
patients that die or suffer handicap as a result. 
8.4.1. Main activities and responsibilities 
 
- Work in a team with one project manager, two Postdoctorals and another research technician.  
- Regular production of writing and verbal reports for discussion with project manager.  
- Continuous application of standard operating procedures (SOP) and assays, with deadlines, 
maintaining meticulously accurate records, according to Good Laboratory Practice (GLP).  
- Maintenance of a clean and organised laboratory.  
- Data statistical analysis and evaluation using Windows 7 and GraphPad Prism 5.  
- Manage the level of stocks and assisting in purchasing chemicals, reagents and laboratory 
equipment.  
- Labelling of chemicals, solutions and reagents to laboratory use, also batch data recording for 
traceability according with Good Laboratory Practice (GLP).  
- Monitoring of animal model of infectious disease and post-mortem tissue collection and 
examination.  
- Experience with bacterial pathogen S. pneumoniae and E.coli.  
- Manage technical records. 
8.4.2. Practical skills gained during this work 
 
- Operating a range of lab equipment varying from microscopes, spectrophotometer, nanodrop, 
centrifuges, varioscan and flow cytometric machine (BD FACScalibur).  
- Application of COSHH and BIOCOSHH.  
- Experience in Good Laboratory Practice (GLP).  
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- Experience in a microbiology laboratory in the area of drug discovery, working with small 
molecules.  
- Monitoring of animal model of infectious disease and post-mortem tissue collection and 
examination.  
- Work under pressure and at flexible hours.  
- Teaching skills, through instructing news laboratory members about the methods and 
techniques. 
 
8.5.  From November 2008 until March 2010 – University of Leicester 
 
I worked as a Research Technician in the Commercial Amoebae Laboratory at University of 
Leicester, under the supervision of Dr James Lonnen. This lab main activities were the study 
of disinfectant and drug efficacy testing against microorganisms, in particular the testing of 
contact lens disinfecting solutions against bacteria, fungi, virus and Acanthamoeba according 
to ISO 14729. Also, the isolation and identification of pathogenic free-living amoeba and 
bacteria from water, environmental and clinical samples. 
8.5.1. Main activities and responsibilities 
 
- Conduct contact lens disinfectant evaluation (biocidal and regimen) assays in accordance with 
ISO/CD14729 against bacteria, fungi, virus and Acanthamoeba. 
- Work in a team with the Lab Director, a Postdoctoral RA, two PhD students and another 
Research Technician. 
- Regular production of written and verbal reports for discussion with the Lab Director to ensure 
that deadlines for studies funded by commercial clients were met. 
- Perform assays for clients according to Good Laboratory Practice (GLP). Those assays 
followed strict Standard Operating Procedures (SOP´s). 
- Maintenance of a clean and organised laboratory. 
- Data statistical analysis and evaluation using SPSS, Excel and Graphpad. 
- Manage level of stocks and assisted in purchasing chemicals, reagents and laboratory 
equipment. Prepare chemicals, solutions and reagents for laboratory use, according to standard 
protocols, also batch data record for traceability according to Good Laboratory Practice (GLP). 
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8.5.2. Practical skills gained during this work 
 
- Operate and maintain a range of lab equipment including microscopes, centrifuges, PCR 
machines and an automated spiral plater. 
- Application of COSHH and BIOCOSHH forms. 
- Work to Good Laboratory Practice (GLP). 
- Handling pathogenic microorganisms including bacteria, fungi, virus and protozoa.  
- Experience of tissue culture using aseptic technique. 
- Performing assays according to International Organization for Standardization (ISO) 
principles. 
 
8.6.  From November 2007 until November 2008 - University of Leicester 
 
I worked as a Research Technician in the PNEUMOPEP project under the supervision of Dr 
Rana Lonnen and Professor Peter Andrew. This project was sponsored by European Comission 
– CORDIS (Community Research and Development Information Service). Undertaken in 
response to the need to find new methods of treatment of disease due to Streptococcus 
pneumoniae. This bacterium is a major cause of community-acquired pneumonia, meningitis, 
bacteraemia and otitis media and it exhibits high rates of multi-drug resistance in countries 
worldwide. More than ever before modern drug discovery is dependent on high-throughput 
screening. Therefore, the drug discovery process is shifting focus from identifying suitable 
candidate drugs - which remains an essential but time-consuming goal - to identifying suitable 
lead compounds in order to maximise the cost-effectiveness and speed of the subsequent lead 
optimisation process. The PNEUMOPEP project achieved its overall aim of finding lead 
compounds for treatment of pneumococcal diseases. Six molecules inhibited pneumolysin and 
were effective in vivo and one was found that acted against pneumococcal neuraminidase A. 
8.6.1. Main activities and responsibilities 
 
- Support and assist with the provision of an efficient histology service, working closely with 
senior academic and technical staff. 
- Conduct in vitro efficacy assays with small molecules using hemolytic assays. 
- Assist in performing in vivo efficacy assays for small molecules using murine models of 
bacteraemia and pneumonia.  
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- Maintain aerobic and anaerobic microbial cultures, as well as collecting, processing and 
analyzing data with various software programs. 
- Conduct antimicrobial assays using small molecules by performing in vitro minimal inhibition 
concentration (MIC) assays. 
- Discs susceptive assays impregnated in small molecules across a range of anaerobic and 
aerobic microorganisms. 
- Laboratory maintenance responsibilities included: chemical inventory, preparing solutions 
and reagents for laboratory use according to defined protocols, safely disposing of waste 
material, maintaining a clean, safe work environment, and assisting in purchasing.  
8.6.2. Practical skills gained during this work 
 
-Experience in a microbiology laboratory in the area of drug discovery, working with small 
molecules. 
- Monitoring of animal models of infectious disease and post-mortem tissue collection and 
examination. 
- Work under pressure at unsociable hours. 
- Experience with anaerobic (ex: Streptococcus pneumoniae) and aerobic (ex: Pseudomonas 
aeruginosa) bacterial pathogenic strains using aseptic technique. 
 
8.7.  From April 2006 until August 2007 – Jardim Vista S.A. 
 
Jardim Vista S.A. is a Portugal leading company on the landscaping field. With a very high 
reputation, achieving top quality designs, construction and maintenance of gardens.  
8.7.1. Main activities and responsibilities 
 
- Control of pests and plant diseases. 
- Quality control of garden plants. 
- Negotiation and direct contact with European suppliers. 
- Manage and coordinate teams for the collection and distribution of plants. 
- Recruitment and supervision of both permanent and seasonal temporary staff. 
- Coordination of irrigation and fertilization, supplies or other inputs according to the activities. 
- Manage work on a number of projects simultaneously to meet deadlines.  
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8.7.2. Practical skills gained during this work 
 
- Irrigation and fertilization knowledge.  
- Teamwork and interpersonal skills. 
- Time management and organization skills. 
- Detection and identification of diseases and pests on ornamental plants. 
9. Publications 
 
9.1.  Patent applications 
 
Due to the commercial nature of the SDDI project, restrictions on the timing of publications 
were imposed by the Intellectual Property Management Group including the patent attorney, to 
avoid disclosure of commercially sensitive data. All my research contributions were written up 
into seven patent applications that were filed on 2011. 
9.2.  Published articles 
 
A1. Chen Yixiang Sandra Germano, Chris Clements, Jesvin Samuel, Ghalia Shelmani, 
Sandrine Jayne, Martin J. S. Dyer and Salvador Macip. 2016. Pro-survival signal inhibition by 
CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. British Journal Haematology. 
175(4):641-651. 
 
This work was based on inhibitor called Dinaciclib that is a cyclin-dependent kinase inhibitor 
with clinical potential in different cancers, including chronic lymphocytic leukaemia (CLL). In 
order to better understand its cytotoxic action, we characterized its effects on signalling 
pathways important for the survival of CLL cells. We found that dinaciclib induced apoptosis 
through the activation of caspases 8 and 9, which was independent of the presence of cytokines 
to mimic the environment of proliferation centres or IGVH mutation status. Moreover, 
treatment with dinaciclib led to the inhibition of oncogenic pathways normally activated in 
stimulated CLL cells, such as STAT3, NF-κB, p38, PI3K/AKT and RAF/MEK/ERK. 
Dinaciclib was also able to block the expression of anti-apoptotic proteins of the BCL2 family 
such as MCL1 and BCL-xL (also termed BCL2L1). Finally, we showed that low concentrations 
of dinaciclib enhanced cell sensitivity to ibrutinib and the BCL2 inhibitor ABT-199, two drugs 
with known effects on CLL. Taken together, our data show that dinaciclib targets multiple pro-
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survival signalling pathways in CLL, which provides a mechanistic explanation for its potent 
induction of apoptosis. They also support a therapeutic application of cyclin-dependent kinase 
inhibitors in CLL in combination with other relevant targeted therapies. 
 
A2. Yixiang Chen, Sandra Germano, Ghalia Shelmani, Diana Kluczna, Sandrine Jayne 
,Martin J. S. Dyer and Salvador Macip. 2017. Paradoxical activation of alternative pro-survival 
pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia. British 
Journal Haematology. In press. 
 
In this work we explored novel therapeutic opportunities for B-cell malignancies, we evaluated 
the effects of MEK inhibitors (MEKi) on chronic lymphocytic leukaemia (CLL). We found that 
none had a significant effect on CLL viability, despite inhibiting signaling. Paradoxically, 
MEKi promoted the accumulation of active MEK and CRAF, reduced the expression of 
negative regulators of the pathway and augmented AKT signaling. Combining MEKi and 
phosphoinositide 3-kinase (PI3K) inhibitors antagonized this effect and induced cell death. We 
propose that MEKi-mediated activation of pro-survival pathways explains their low toxicity in 
CLL and that inhibition of both RAF/MEK/ERK and PI3K/ AKT signaling could overcome 
single-agent resistance. 
9.3. Submitted articles 
 
SA1. Diana Kluczna, Ghalia Shelmani, Yixiang Chen, Mireia Casulleras, Laura Castilla, Jason 
Rodencal, Sandra Germano, Sandrine Jayne, Ben Kennedy, Simon Wagner, Costas Balotis, 
Martin J. S. Dyer and Salvador Macip. 2017. Submitted to: British Journal Haematology. 
 
This article focus is about NOTCH1 mutations poor prognostic factor for Chronic Lymphocytic 
Leukaemia (CLL), associated with resistance to rituximab and increased risk of Richter’s 
transformation. To characterize the role of NOTCH1 mutation in drug sensitivity, we first 
genotyped exon 34 (including the 3’-UTR) in 147 CLL patients. We found mutations in 13/106 
(12.3%) of a random cohort and 13/41 (26.8%) of patients with trisomy 12. The most common 
mutation, seen in 92.3%, was the CT deletion in the PEST domain. We also found two 
previously unreported frame-shift mutations (a 38bp deletion and a nucleotide insertion) in the 
transactivation domain, resulting in loss of the PEST domain. We next treated NOTCH1 
mutated and wild type patient cells with different targeted inhibitors. No differences were 
observed with most of the drugs tested. However, a subgroup of NOTCH1 mutated patients 
  
37 
showed increased resistance to BCL2 inhibitor venetoclax. To extend our study, we compared 
Rec-1, a malignant B cell line that harbours a NOTCH1 mutation, with wild-type cell lines 
JVM3 and Mec-1. We found that Rec-1 were more sensitive to inhibition of NF-κB and γ-
secretase. Moreover, combination of ibrutinib with either γ-secretase or BCL2 inhibitors 
showed synergy in the mutated cells. Our results show that NOTCH1 mutation in CLL defines 
a subgroup of disease with specific sensitivities to combinations of targeted agents that may 
allow new therapeutic approaches. 
10. Conferences and seminars 
 
- 5th of September 2012: Society for General Microbiology (SGM). Autumn Conference at 
University of Warwick.  
- 6th of November 2008: Quarterly meeting of the EU consortium, Oral presentation of my work 
on Novel antimicrobials.  
- 25th of May de 2005 – “Problemática dos Incêndios: o que nos reserva o futuro?” seminar at 
Universidade do Algarve. 
- 19th of May 2004 –“Jornadas de Construções de Jardins e Ornamentais”, at Universidade do 
Algarve. 
- 12th of March 2004 – “1.º Encontro com a Terra “A Mobilização do Solo e a Erosão”, in 
Tavira. 
- 29th of March 2001 – “Seminário de Saúde Ambiental”, at Universidade do Algarve by 
Associação Internacional de Estudantes de Agricultura. 
- 19th and 20th of October 2000: “Agricultura Sustentável e Actividades Complementares” at 
Universidade do Algarve. 
11.  Other competences 
11.1. Courses and Training 
 
- Level 3 HACCP Training Course (2016).  
- Holder of a personal Home Office License, Module 1-5, Animals (Scientific procedures), 
Act 1986 (2015). 
- Good clinical practices Level 1 (2014). 
- Certificado de competências pedagógicas (CCP) (2007). 
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- Commercial trade, in CEGOC (2006). 
11.2. IT skills 
 
Excellent Proficiency in Microsoft Office, GraphPad Prism and SPSS. 
 
11.3. Languages 
 
 Understanding Speaking 
Writing 
Listening Reading Spoken interaction Spoken production 
English C1 
Proficient 
user 
C1 
Proficient 
user 
C1 
Proficient 
user 
C1 
Proficient 
user 
C1 
Proficient 
user 
Spanish C2 
Proficient 
user 
C2 
Proficient 
user 
C2 
Proficient 
user 
C2 
Proficient 
user 
C2 
Proficient 
user 
 
12.  Critical point of view about professional evolution 
 
The degree in Engenharia Agronómica – Ramo Hortofruticultura at the Universidade do 
Algarve, where technical aptitudes where acquired were vital for professional performance of 
the functions mentioned in this report. Subsequently, the professional experience allowed the 
acquisition of technical knowledge essential to the proper performance of the functions 
executed during all these years. These knowledge acquisition also enabled a development of 
critical analysis of various subjects. There were also relevant capacities developed as team 
leader, the ability to solve problems in short periods of time and the ability to work as a team 
or independently with defined deadlines. 
 
Working in Jardim Vista S.A. from 2006 until 2007 it helped developing skills in fertilization, 
chemical control and organization. In November 2007 I moved to the UK where I worked in 
University of Leicester for 9 years as Research Technician/Research Assistant in areas such as 
molecular biology and microbiology. I participated in several UK and European research 
projects, from those projects I contributed to several patent applications and articles. In 
September 2016, I moved back to Portugal where I worked as a Research Technician in 
Universidade do Algarve on the project “Cloning of fragments of the genes callose synthase 
and xyloglucan endotransglucosylase from Citrus x clementina hort. ex Tanaka “Fina” and 
Citrus sinensis (L.) Osbeck “Valencia late”. In April 2017 I joined Syngenta in Moncarapacho, 
as a Senior Grower.  
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I have a very diversified profile in science, considering that I worked on projects related with 
respiratory infection diseases, water quality and cancer, where I learn many different lab 
techniques, protocols and worked with a lot of different lab equipment.  
From 2007 until 2016 my experience was based on science related to infectious diseases and 
oncology, even so all the subjects that I had lecturers at Universidade do Algarve help me to 
know and to better understand all the molecular biology techniques required for these jobs.  
Thus, and in addition to the technical skills acquired, others were also relevant, among which 
can be broadly highlighted, the capacity of planning and organisation, in accordance with the 
resources available, and with the priorities and deadlines defined and reassessed in the face of 
unforeseen changes. Given the need to define priorities in order to meet the objectives stipulated 
and adequately manage the working time related to each task were also developed competences 
relevant to the level of the guidance for results. From the professional point of view various 
skills where developed, relevant knowledge, practical experience and sense of responsibility. It 
is also worth mentioning the experience gained during these years in statistical programs, 
namely GraphPad and SPSS, and in the preparation of technical reports and as coauthor of 
scientific articles. In the University of Leicester I had the opportunity of supervise students. 
At the level of professional experience, some constraints on the evolution of professional 
experience can also be pointed out, which can be considered weak points or threats. 
It can be pointed out as a weak point that I performed functions centred mainly in a very specific 
area, not covering other areas in the field of Agronomic Engineering. 
It also adds as a weak point the lack of willingness to exercise tasks considered less priority but 
still with some importance in good professional performance. Even if the projects that I 
collaborate, at University of Leicester weren’t related to agriculture, all the techniques learnt 
are used in plant biotechnology.  
Since I finished my degree until today, all the experiences gained during that time gave me 
support and knowledge to hold now a position as a Senior Grower at Syngenta Flowers.   
The master's degree in “Hortofruticultura” will allow me to continue my work, as well as to 
promote and deepen my knowledge in a specific way and at the same time help me to better 
execute my most recent functions.  
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Summary 
 
Dinaciclib is a cyclin-dependent kinase inhibitor with clinical potential in 
different cancers, including chronic lymphocytic leukaemia (CLL). In order 
to better understand its cytotoxic action, we characterized its effects on sig-
nalling pathways important for the survival of CLL cells. We found that 
dinaciclib induced apoptosis through the activation of caspases 8 and 9, 
which was independent of the presence of cytokines to mimic the environ-
ment of proliferation centres or IGVH mutation status. Moreover, treat-ment 
with dinaciclib led to the inhibition of oncogenic pathways normally 
activated in stimulated CLL cells, such as STAT3, NF-jB, p38, PI3K/AKT 
and RAF/MEK/ERK. Dinaciclib was also able to block the expression of 
anti-apoptotic proteins of the BCL2 family such as MCL1 and BCL-xL (also 
termed BCL2L1). Finally, we showed that low concentrations of dinaciclib 
enhanced cell sensitivity to ibrutinib and the BCL2 inhibitor ABT-199, two 
drugs with known effects on CLL. Taken together, our data show that 
dinaciclib targets multiple pro-survival signalling pathways in CLL, which 
provides a mechanistic explanation for its potent induction of apoptosis. They 
also support a therapeutic application of cyclin-dependent kinase inhibitors in 
CLL in combination with other relevant targeted therapies. 
 
 
Keywords: dinaciclib, CDK inhibitors, chronic lymphocytic leukaemia, 
 
 
Chronic lymphocytic leukaemia (CLL) is a B-cell malignancy 
characterized by a progressive accumulation of functionally 
incompetent B lymphocytes in the peripheral blood, lymph 
nodes and bone marrow (Chiorazzi et al, 2005; Mittal et al, 
2014). Recent therapeutic strategies in CLL have significantly 
improved the survival of patients, although it remains incur-
able. Thus, efforts to develop effective treatments are still 
necessary (Dyer et al, 2013). Although CLL cells in peripheral 
blood are mostly non-dividing and easily targeted by many 
inhibitors, a small number of cells residing in the bone mar-
row and lymphoid nodes have higher chemoresistance and 
proliferative capacity (Meads et al, 2008). A variety of cytoki-
nes, including T lymphocyte-expressed CD40 ligand 
(CD40LG or CD154), BAFF (also termed TNFSF13B) and 
interleukin 4 (IL4), are produced within this microenviron-
ment niche and, together with stromal cells, nurse-like cells 
and T cells, are thought to be the major cause of resistance 
CLL therapy (ten Hacken & Burger, 2014). To mimic this 
 
 
 
microenvironment in vitro, a number of models have been 
established, including stimulation with soluble CD154/IL4, 
and co-cultures with CD154-expressing fibroblasts together 
with IL4 (Willimott et al, 2007a). Under these conditions, the 
expression of anti-apoptotic members of the BCL2 fam-ily, 
particularly BCL-xL (also termed BCL2L1) and MCL1, are 
greatly increased, which contributes to the resistance to 
spontaneous- and drug-induced apoptosis in CLL (Willimott 
et al, 2007a,b; Vogler et al, 2009).  
B-cell receptor (BCR) signalling can be induced by ligand-
independent stimulation and/or ligation of auto-antigens 
present in the microenvironment. Once engaged, it activates 
pro-survival signals such as the RAF/mitogen-activated pro-
tein kinase-extracellular signal-regulated kinase/extracellular 
signal-regulated kinase) (RAF/MEK/ERK), phosphatidylinosi-
tol 3-kinase/a serine/threonine kinase (PI3K/AKT), p38 (also 
termed MAPK14), nuclear factor (NF)-jB and signal trans-
ducer and activator of transcription 3 (STAT3 pathways, 
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which play a pathogenic role in CLL (Kawauchi et al, 2002;  
Ogasawara et al, 2003; Pickering et al, 2007; Ringshausen  
et al, 2002; Hazan-Halevy et al, 2010; Cunı et al, 2004; 
Sainz-Perez et al, 2006; Rozovski et al, 2014). Nearly half of 
CLL cases have high levels of constitutively phosphorylated 
ERK1/2 (Muzio et al, 2008) and in freshly isolated CLL cells, 
phosphorylated p38 is predominately activated (Sainz-Perez et 
al, 2006). PI3K is also frequently activated in CLL cells and its 
inhibition induces apoptosis in some models (Cunı et al, 
2004). PI3K/AKT activates NF-jB and the loss of AKT and 
NF-jB is also associated with apoptosis in these cells (Cunı et 
al, 2004). NF-jB RelA/p65 activation correlates 
chemoresistance and poorer clinical outcome in CLL (Fur-man 
et al, 2000; Cunı et al, 2004; Hewamana et al, 2008). 
Moreover, NF-jB activation can be regulated by STAT3 (Liu 
et al, 2011), which is constitutively phosphorylated at serine 
727 in CLL cells (Hazan-Halevy et al, 2010; Rozovski et al, 
2014).  
Disruption of activated pro-survival signals such as these 
has become a field of major interest in the development of 
antineoplastic drugs, and many small molecular kinase inhi-
bitors that selectively target them have already been devel-
oped (Dyer et al, 2013). Finding treatments that target 
multiple signalling pathways simultaneously in diseases such 
as CLL is important to avoid recurrences and eventually pro-
vide a curative strategy (Dyer et al, 2013).  
Cyclin-dependent kinases (CDKs) are essential in the regu-
lation of cell division, cell-cycle progression and gene tran-
scription, and therefore deregulated in many cancers 
(Malumbres & Barbacid, 2009). Their inhibition represents a 
promising therapeutic approach in blood malignancies 
(Blachly et al, 2016). Although initial clinical studies with the 
CDK inhibitor, Alvocid, showed high toxicity due to hypera-
cute tumour lysis, there have been successful trials with sub-
sequent inhibitors (Blachly et al, 2016). Dinaciclib (MK-7965, 
formerly SCH727965), a novel, selective CDK1-4/7/9 
inhibitor with improved therapeutic index, was found to induce 
apoptosis in CLL cells (Johnson et al, 2012). It has already 
been tested in initial trials for solid tumours (Nemu-naitis et 
al, 2013), myeloma (Kumar et al, 2015) and refrac-tory CLL 
(Flynn et al, 2015). Encouraging Phase I and II results provide 
a rationale for the use of dinaciclib alone or in combination 
with immunotherapies in CLL and lym-phoma (Blachly et al, 
2016). However, the molecular events that contribute to 
dinaciclib-induced apoptosis of malignant B cells are not fully 
understood.  
Here, we studied the effects of dinaciclib on the pro-survi-
val signals present in CLL to better understand the mecha-
nisms involved defining its therapeutic potential. We show that 
dinaciclib simultaneously targets several pro-survival sig-
nalling pathways and suppresses expression of anti-apoptotic 
proteins to induce a caspase-dependent cell death. We also 
present evidence that supports the hypothesis that dinaciclib 
could be of therapeutic use in CLL, alone or in combination 
with other targeted drugs. 
 
 
 
Methods 
 
Cell culture and reagents 
 
MEC-1, ESKOL and JVM3 cell lines were cultured in 
complete medium (RPMI-1640 medium with 10% fetal bovine 
serum, 2 mmol/l L-glutamine, 50 u/ml penicillin and 50 mg/ml 
streptomycin) at 37°C in incubator containing 5% CO2. 
Peripheral blood samples were obtained from CLL patients 
attending clinics at the Leicester Royal Infirmary (Leicester, 
UK) following informed consent and approval from the local 
Research Ethics Committee and in accordance with the Decla-
ration of Helsinki. All patients, diagnosed according to the 
International Workshop on Chronic Lymphocytic Leuksemia 
2008 guidelines (Hallek et al, 2008), had been treatment-free 
for at least 6 months and had a white blood cell count >50 9 
109/l. Peripheral blood mononuclear cells (PBMCs) were 
separated from whole blood by density centrifugation. 
Heparinized whole blood was diluted 1:1 with phosphate-buf-
fered saline (PBS) and gently layered onto 15 ml Ficoll (Histo-
paque 1077, Sigma-Aldrich, Poole, UK) prior to centrifugation 
at 400 g for 30 min. The mononuclear cell layer was removed 
from the interphase, washed and resuspended in RPMI-1640 
supplemented with 10 ng/ml IL4 and CD154 (CD40LG) to 
maintain cell survival in vitro. Alternatively, mouse fibroblast 
L cells (NTL) and NTL cells stably expressing CD154 (NTL/ 
CD154) were used in co-culture experiments to support CLL 
cell survival/proliferation. NTL/CD154 cells were irradiated 
with 30 Gy and then co-cultured with CLL patient cells at a 
ratio of 1:25. The inhibitors dinaciclib (SCH727965), ibrutinib 
(PCI-32765), Entospletinib (GS-9973), Ver155008, BX-912, 
RAF265, Sorafenib, Vemurafenib (PXL4032), Trametinib 
(GSK1120212), MG-132, Fedratinib and ABT-199 used in 
this study were obtained from Selleckchem (Houston, TX, 
USA). Z-Vad-Fmk was bought from Sigma-Aldrich. 
 
 
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] assay 
 
The CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI, USA) was used to estimate 
cell viability and proliferation, according to the manufac-
turer’s instructions. Briefly, 100 ll 0 25 9 106/ml cells from 
cell lines or 2 9 106/ml CLL cells were seeded in 96-well 
plates. Inhibitors were added at different concentrations for 48 
h before 20 ll MTS was added to each well. After incuba-tion 
for 1–3 h at 37°C, the absorbance at 490 nm was recorded on 
a TECAN infinite F50 reader (Labtech Interna-tional, 
Uckfield, UK). Cell viability was calculated based on the 
reducing potential of the viable cells using a colourimet-ric 
reaction. Assays were performed in triplicate and repeated on 
at least two independent occasions and results were plot-ted 
and analysed using GraphPad Prism 6 (GraphPad Soft-ware 
Inc., San Diego, CA, USA). 
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Cell-cycle analysis 
 
Cells were harvested, fixed with precooled 70% ethanol at 
20°C overnight, and then stained with propidium iodide (PI; 
Sigma-Aldrich) diluted in PBS containing RNase A at 37°C 
for 30 min in the dark. Cell-cycle distribution was then 
determined using a FACS Canto II cytometer (BD Bio-
sciences, Franklin Lakes, NJ, USA). 
 
Cell death analysis 
 
Cells were harvested and stained with Annexin V (Sigma-Aldrich) 
for 15 min at 4°C. Percentages of apoptotic cells (posi-tive for 
Annexin V) were determined by flow cytometry using a FACS 
Canto II cytometer (BD Biosciences) following the man-
ufacturer’s instructions. Alternatively, cell death was measured by 
staining the cells with PI for 30 min at 4°C and the percent-age of 
PI-positive cells (dead) determined by flow cytometry. 
 
Western blotting 
 
Total protein was prepared in radioimmunoprecipitation assay 
lysis buffer [10 mmol/l Tris pH 7 4, 150 mmol/l NaCl, 1% 
TritonX-100, 0 1% sodium deoxycholate, 0 1% sodium 
dodecylsulfate (SDS), 5 mmol/l EDTA] supplemented with 
protease inhibitor cocktail (Sigma-Aldrich) and phosphatase 
inhibitor cocktail 2 (Sigma-Aldrich). Proteins were separated 
with SDS-polyacrylamide gel electrophoresis and incubated 
with specific antibodies. Protein bands were visualized and 
quantified with an Odyssey system (Pierce, Waltham, MA, 
USA). The antibodies used were: ERK, phospho-ERK 
(Thr202/Tyr204), AKT, phosphor-AKT (Ser473), IjBa, phos-
phor-IjBa (Ser32/36), STAT3, phosphor-STAT3 (Tyr705), 
p38, phosphor-p38 (Thr180/Tyr182), PARP, caspase-8 and 
caspase-9 (Cell Signaling Technology, Danvers, MA, USA); 
BCL2 (Dako, Santa Clara, CA, USA); b-actin (Millipore); 
BCL-xL/S, MCL1 and NF-jB(p65) (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA). Fluorescent-conjugated secondary 
anti-rabbit or anti-mouse antibodies were purchased from Enzo 
Life Sciences (Farmingdale, NY, USA). 
 
Results 
 
CLL cells are highly sensitive to dinaciclib 
 
In order to better understand the sensitivity of CLL cells to the 
CDK inhibitor dinaciclib, we compared its effects on the 
viability of MEC-1, an Epstein–Barr virus-positive B-cell line 
derived from a patient with CLL that is often used as a model 
for this disease (Stacchini et al, 1999), to that of different tar-
geted inhibitors of pro-survival pathways often activated in 
leukaemia. We selected other drugs that have been studied in 
the context of leukaemia, such as MG-132 [a proteasome inhi-
bitor (Guo & Peng, 2013)], ibrutinib [a BTK inhibitor (Byrd et 
al, 2013; Danilov, 2013)], vemurafenib [a BRAFV600E 
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inhibitor (Samuel et al, 2014)], ver155008 [a HSP70 inhibitor 
(Reikvam et al, 2013)], BX-912 [a PDK1 inhibitor targeting 
the PI3K/AKT pathway (Feldman et al, 2005)] and fedratinib 
[a Jak/STAT pathway inhibitor (Pardanani et al, 2007)]. 
Dinaciclib demonstrated more than 100-fold greater inhibi-
tory effects on the metabolic activity of MEC-1 than any of 
the other drugs tested (Fig 1A), confirming its potential as a 
therapeutic approach for CLL and consistent with recent 
results that showed the strong cytotoxic effects of CDK inhibi-
tors in CLL (Johnson et al, 2012; Paiva et al, 2015; Sylvan et 
al, 2016). We determined that the effects of dinaciclib on cell 
viability were the consequence of a dose-dependent increase in 
cell death but not cell cycle arrest, as tested by PI staining (Fig 
1B). Specifically, we found that this was due to the induction 
of apoptosis (Fig 1C). Cell death induction was progressive 
and reached a maximum after 48 h (Fig 1D). Of note, these 
figures show that a fraction of cells were resistant to even the 
highest concentration of dinaciclib tested, for rea-sons that 
will need to be elucidated. A similar response to these drugs 
was also observed in other malignant B-cell lines, such as 
ESKOL and JVM3 (Fig S1A).  
We next confirmed these results in primary CLL cells 
(Table S1) cultured in the presence of CD154 and IL4 to 
mimic the protective microenvironment of proliferation cen-
tres. Dinaciclib was also able to reduce cell viability at low 
concentrations under these conditions (Fig 1E), showing a 
higher effect than the other inhibitors. This was also dose-
dependent (Fig 1F), with a 50% inhibitory concentration 
below 5 nmol/l, and not determined by patient IGVH muta-
tion status (Fig 1G). We could not find any clinical parame-
ters that strongly determined a change in sensitivity to 
dinaciclib, except perhaps a higher ratio of deletions in more 
resistant cells (Table S2). Similar results were also observed in 
the primary CLL patient cells co-cultured with mouse 
fibroblast L (NTL) cells stably expressing CD154 and 
supplemented with IL4, an alternative stimulation system (Fig 
S1B). Taken together, these data support the hypothesis that 
dinaciclib is highly toxic for malignant B cells at sub-
micromolar concentrations, with effects stronger than any of 
the inhibitors of pro-survival signals tested, and that this is due 
to the induction of apoptosis. Also, we showed that dinaciclib 
can strongly affect cell viability even in different culture 
conditions that mimic protective microenviron-ments, which 
underscores its potential to target resistant CLL cells. 
 
 
 
Dinaciclib-induced toxicity in CLL is 
dependent on caspase activation 
 
We further explored the apoptotic effects of dinaciclib on CLL 
cells by analysing the activation of the caspase pathway. Our 
data showed that dinaciclib can activate caspase 8 and caspase 
9, and induce PARP cleavage in CLL patient cells (Fig 2A), 
which indicates induction of apoptosis with involvement of 
both the intrinsic (mediated by caspase 9) 
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Fig 1. MEC-1 cells are highly sensitive to dinaciclib. (A) MEC-1 cell viability measured by MTS assay. Cells were treated with various small mole-
cule inhibitors (0 001 to 10 lmol/l) or dimethylsulfoxide (0 lmol/l) for 48 h. Experiments were performed in triplicate and repeated at least two times. 
Graphics show mean values and error bars represent standard deviation, as in all the other panels of this figure. (B) Percentage of cells in each phase 
of the cell cycle, as measured by propidium iodide (PI) staining of MEC-1 cells treated with dinaciclib for 72 h. +: positive control (0 1% Triton X). 
Experiments were performed in triplicate and repeated on at least two independent occasions. (C) Induction of apoptosis in MEC-1, as measured by 
FACS analysis of Annexin V-stained cells. Cells were treated with inhibitors for 72 h. Graphics show percentage of apop-totic cells (Annexin 
positive). (D) Time-course analysis the induction of apoptosis in MEC-1 cells treated with different concentrations of dinaci-clib, as measured by PI 
staining. Experiments were performed in triplicate and data were expressed as mean standard deviation in all the panels of this figure. (E) CLL 
patient cell viability measured by an MTS assay. Cells were cultured for 24 h in the presence of 10 ng/ml IL4 and CD154 and then treated with 0 01 
and 0 1 lmol/l of different inhibitors for 48 h. Between 3 and 10 samples were tested for each inhibitor, and experiments were performed in triplicate. 
Graphics show mean values and error bars represent standard deviation. (F) Primary cells (from Patients 2, 5, 8, 9, 10, 14, 16, 20, 26, 27, 28, 31 and 
32 in Table S1) were cultured as above and treated with dinaciclib at various concentrations for 48 h. (G) Viability of primary patient cells treated 
with different concentrations of dinaciclib for 48 h, as measured by MTS assay. Patient 9 (IGVH mutated) and Patient 32 (unmutated) are shown as 
representative cases. Experiments were performed in triplicate and repeated on at least two independent occasions. Data are expressed as mean 
standard deviation. 
 
and extrinsic (mediated by caspase 8) pathways (Parrish et al, 
2013). We next treated CLL cells with the pan-caspase inhibi-
tor Z-Vad-Fmk before exposing them to dinaciclib. The pres-
ence of the caspase inhibitor partially reduced the PARP 
cleavage and apoptosis induced by dinaciclib (Fig 2B), sug-
gesting that the cytotoxicity of dinaciclib in CLL is, at least, 
partly dependent on the activation of the caspase cascade. 
 
Dinaciclib inhibits pro-survival signals in CLL cells 
 
To further investigate the molecular events that determine the 
effect of dinaciclib on CLL cell survival, we measured the 
 
 
activation status of multiple pro-survival oncogenic signalling 
pathways that have been reported to be upregulated in B cell 
malignancies, such as STAT3, NF-jB, p38, PI3K/AKT and 
RAF/MEK/ERK (Kawauchi et al, 2002; Ringshausen et al, 
2002; Ogasawara et al, 2003; Cunı et al, 2004; Sainz-Perez et 
al, 2006; Pickering et al, 2007; Hazan-Halevy et al, 2010; 
Rozovski et al, 2014). The phosphorylation level of STAT3 
(Tyr705), IjBa (Ser32/36), p38 (Thr180/Tyr182), AKT 
(Ser473) and ERK (Thr202/Tyr204) were assessed as markers 
of activation of these pathways in MEC-1 cells. As shown in 
Fig 3A (0 1 lmol/l dinaciclib) and Fig S2A (0 01 lmol/l 
dinaciclib), in treated cells there was a marked decrease in 
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Fig 2. Cell death induced by Dinaciclib in primary cells is dependent on caspase cleavage. (A) Western blot showing caspase 9, caspase 8 and PARP 
cleavage in CLL primary cells (P1 and P3). Cells were cultured as above and treated with dinaciclib for 16 h. b-actin served as a loading control. The 
graph shows quantitation of these two blots, expressed as the ratio of cleaved to uncleaved proteins, normalized to b-actin. (B) Patient cells (P22) 
were cultured as above and treated with 25 lmol/l caspase inhibitor Z-Vad-Fmk for 1 h before being treated with different concentrations of 
dinaciclib for 16 h. Numbers show percentage of apoptotic cells in the same experiment, as measured by Annexin staining. 
 
 
the phosphorylation of STAT3 and IjBa, together with a more 
gradual decrease in the phosphorylation of p38. On the other 
hand, AKT and ERK phosphorylation started to decline after 8 
h, following an initial increase. A substantial reduc-tion in all 
these signals was evident after 12 h of treatment (Fig 3B; Fig 
S2B). Of note, the levels of phosphorylated pro-teins did not 
change in untreated cells cultured for the same time, showing 
that the inhibition of the signalling pathways was indeed due to 
the effects of dinaciclib and not an arte-fact determined by 
spontaneous protein degradation (see Fig-ure S2B). Moreover, 
these changes in the signalling pathways occurred before 
PARP cleavage and the induction of apopto-sis, which started 
after 12 h of exposure to dinaciclib (see Fig 3A and Fig S2A), 
suggesting they are an early event in the cellular response to 
the drug.  
Next, we confirmed these results in primary CLL cells. We 
found that the phosphorylation of STAT3, IjBa and p38 
decreased after 12 h exposure to dinaciclib in cells cultured in 
the presence of CD154/IL4 (Fig 3C). Moreover, we observed 
that P-ERK, P-AKT (Fig 3D) and NF-jB (Fig 3E) were also 
inhibited by dinaciclib in primary cells. Of note, although a 
similar response was observed in ESKOL cells, JVM3 cells 
showed reduction in the phosphorylation of AKT  
but not in that of ERK, perhaps due to an over-activation of 
this pathway driven by the BRAFK601N mutation present in 
these cells (Fig S2C).  
We also observed that the levels of MCL1, an anti-apopto-
tic protein of the BCL2 family, quickly decreased in MEC-1 
after treatment with dinaciclib in a time and concentration 
dependent manner, which correlated to PARP cleavage and 
induction of apoptosis (see Fig 3A and Fig S2A). This is con-
sistent with recent reports showing that MCL1 expression was 
decreased by dinaciclib in various cancer cells (Fu et al, 2011; 
Chen et al, 2015; Gregory et al, 2015; Varadarajan  
et al, 2015). We confirmed that dinaciclib inhibited both 
 
 
 
MCL1 and BCL-xL in stimulated primary cells and MEC-1 
(Fig 3F). However, its effects on BCL2 were patient-depen-
dent (Fig 3G). As the levels of BCL2-related proteins, such as 
MCL1, BCL-xL and BCL2, have been linked to the resistance 
of malignant B cells to apoptosis (Kitada et al, 1998; Pepper 
et al, 2008), this inhibition could contribute to the cytotoxic-
ity of dinaciclib. Taken together, our data shows that dinaci-
clib has an inhibitory effect on several oncogenic signalling 
pathways usually activated in malignant B-cells, which pro-
vides a mechanism to explain its potent effects in these cells. 
 
Positive effects of dinaciclib in combination therapies 
 
Despite their strong apoptotic effects on malignant B cells, the 
efficacy of CDK inhibitors as monotherapy has not been as 
successful as expected (Bose et al, 2013). Dinaciclib has only 
a 54% overall response rate in relapsed/refractory CLL 
patients and a tumour lysis syndrome is sometimes induced 
(Flynn et al, 2015). This suggests that combination with other 
targeted therapies could improve its clinical impact. To 
explore this possibility, we assessed the combination of 
dinaciclib with low concentrations of other specific inhibitors 
relevant to B cell malignancies, such as ABT-199 (BCL2 inhi-
bitor), iburitinib (BTK inhibitor) and entosplentinib (SYK 
inhibitor). The effects of ibrutinib and ABT-199 on MEC-1 
survival were increased by combination with nanomolar con-
centrations of dinaciclib, while there was no variation with 
entospletinib (Fig 4A). The greatest effect was seen with 
ABT-199, which could trigger only low levels of cell death 
(~20%) when used alone, induced over 80% apoptosis when 
combined with 0 01 lmol/l dinaciclib. This is consistent with 
previous reports showing that CDK inhibitors sensitize CLL 
cells to BH3 mimetics, such as ABT-737 (Paiva et al, 2015). 
For ibrutinb, the increase in cell death was from ~50 to ~90%. 
A similar response was observed in stimulated 
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Fig 3. Dinaciclib inhibits pro-survival signals in CLL cells. (A) Western blot performed on lysates of MEC-1 cells treated with dinaciclib at 0 1 
lmol/l concentration and collected at 2, 4, 6, 8 and 10 h after treatment. Levels of activation of signalling pathways was measured by the 
phosphorylation of Erk (Thr202/Tyr204), Akt (Ser473), IjBa (Ser32/36), STAT3 (Tyr705) and p38 (Thr180/Tyr182). MCL1 (MCL-1) and PARP 
levels were also measured. Right-panel graph shows quantitation the Western blot bands normalized to b-actin and expressed as relative to con-trol 
(0 h) treatment. (B) Representative Western blot of MEC-1 cells treated with dinaciclib for 12 h. Levels of total and phosphorylate Erk and Akt were 
measured, as well as PARP cleavage. (C) Representative Western blot of patient CLL cells (P21 and P12) cultured as described and trea-ted with 
dinaciclib for 12 h. Levels of total and phosphorylated STAT3, IjBa and p38 were measured. (D) Same as above, measuring the levels of P-ERK, 
ERK, P-AKT and AKT, as well as PARP cleavage. (E) Same as above, showing levels of NF-jB (p65 and p50). (F) Same as above, showing levels 
of MCL1 and Bcl-xL in CLL patient cells and MEC-1 treated with dinaciclib. (G) Same as above, showing levels of BCL2. 
 
primary cells (Fig 4B). The increase in apoptosis induced in 
this case by ibrutinib was from ~60 to ~90%, and by ABT-199 
from ~80 to ~90%. These results suggest that nanomolar 
concentrations of dinaciclib could sensitize CLL cells to ibru-
tinib or BCL2 inhibitors, potentially enhancing their effects 
and reducing chemoresistance. 
 
 
Discussion 
 
Despite having been developed many years ago, CDK inhibi-
tors have only recently been considered for antineoplastic 
therapies. First-generation CDK inhibitors, such as flavopiri-
dol (PHA-793887) and roscovitine (CYC202), had a narrow 
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Fig 4. Dinaciclib enhances sensitivity of CLL 
cells to ibrutinib and ABT-199. (A) Percentage 
of apoptotic MEC-1 cell in cells treated with 
different concentrations of dinaciclib for 48 h, 
either alone or in combination with 0 1 lmol/l 
ABT-199, 10 lmol/l ibrutinib or 10 lmol/l 
entospletinib, as measured by propidium iodide 
staining. Graphs show average of three 
independent experiments. (B) Same for combi-
nations of dinaciclib with 0 1 lmol/l ABT-199 
and 10 lmol/l ibrutinib on CLL patient cells 
(P22) cultured for 24 h in the presence of 10 
ng/ml IL4 and CD154. Graphs show average of 
two independent experiments. 
 
 
therapeutic window and low selectivity (Blachly & Byrd, 
2013; Blachly et al, 2016) Dinaciclib was designed to maxi-
mize the therapeutic index and minimize the toxicity associ-
ated with this drug type. It specifically shows a strong and 
selective inhibition of CDK1, CDK2, CDK5 and CDK9 and 
was shown to induce death in various cancer cells (Parry et al, 
2010; Paruch et al, 2010). Dinaciclib has already been 
evaluated in clinical trials and results show that it has 
encouraging activity in relapsed/refractory CLL (Fabre et al, 
2014; Flynn et al, 2015).  
In this study, we explored the effects of dinaciclib on pro-
survival signalling pathways in CLL cells. Our data confirmed 
that malignant B cells have a high sensitivity to dinaciclib, 
even in the presence of stimulatory cytokines that recapitu-late 
the protective features of the microenvironment in pro-
liferation centres. Reaching these cells is necessary for a 
curative effect in CLL, because they are less sensitive to ther-
apies than circulating cells and may thus be the cause of 
resistant disease (Dyer et al, 2013). Importantly, the concen-
tration of dinaciclib needed to exert an effect on B cell sur-
vival is several orders of magnitude below that of other small 
molecule inhibitors we tested. All this greatly supports the 
clinical relevance of dinaciclib as a treatment for CLL. How-
ever, our results also show a percentage of refractory cells 
(10–25%), even at concentrations above therapeutic limits (see 
Figs 1A–C), which suggest that dinaciclib may not be a 
monotherapy of choice.  
It has been previously reported that CDK inhibitors pro-
mote apoptosis in different cancer cells via suppression of Rb 
phosphorylation (Parry et al, 2010; Fu et al, 2011) or in a 
JNK/p38-dependent manner (Paiva et al, 2015). Our data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
showed that this requires the activation of caspase 8 and 9, 
suggesting an involvement of both the extrinsic and intrinsic 
pathways. The use of patients in our experiments with TP53 
mutations or deletions (see Table S1) indicates that dinaci-
clib-induced apoptosis can also be TP53-independent.  
We show that treating CLL cells with dinaciclib has wide 
ranging effects and interferes with at least five major onco-
genic pathways that are often hyperactivated in these cells: 
RAF/MEK/ERK, p38, PI3K/AKT, NF-jB and STAT3. Given 
the fact that these are well known pro-survival signals, it is 
reasonable to assume that their inhibition would greatly con-
tribute to the induction of cell death. Moreover, these are early 
effects, observed before the activation of the apoptotic 
machinery and thus would play a role in the downstream 
events. It is likely that the strong effect of dinaciclib on CLL 
survival is partly mediated by the combined inhibition of two 
or more of these oncogenic pathways.  
According to our results, this molecular response of CLL 
cells to dinaciclib follows two different phases. The early 
effects include an immediate inhibition of STAT3 and NF-jB 
signalling. In parallel, the ERK, p38 and AKT pathways show 
a more gradual inhibition. Eventually, all these signals are 
suppressed, and then apoptosis begins. This suggests that the 
first three pathways may be directly inhibited by dinaciclib, 
while the latter two may be an indirect or secondary response. 
Of note, dinaciclib could effectively induce cell death in 
JVM3 cells despite the fact ERK phosphorylation was not 
inhibited, suggesting that either this effect may be dispensable 
in triggering apoptosis or inhibiting other path-ways 
simultaneously is sufficient. The importance of sig-nalling 
pathways in cell responses to dinaciclib is likely to 
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vary in different CLL patients. For instance, not all patients 
have a high level ERK activation (Muzio et al, 2008) and 
AKT Serine 473 phosphorylation, a marker of its activation, 
was very low in unstimulated CLL cells (Ringshausen et al, 
2002). These data support the view that the signalling net-
works in CLL cells are very diverse and complex and that 
drugs that can target more than one of these signals are likely 
to be effective at treating a greater number of patients.  
It remains to be determined which of these pathways needs 
to be inhibited for dinaciclib to induce cells apoptosis and 
which inhibition may be dispensable. Our data suggests that 
induction of apoptosis is linked to an early inhibition of 
STAT3, NF-jB and p38 signalling, which is then followed by 
blocking of the PI3K/AKT and RAF/MEK/ERK pathways. 
NF-jB has been recently shown to be essential for CDK inhi-
bitors to induce apoptosis in CLL cells (Cosimo et al, 2013). 
This is consistent with the fact that cytokines expressed in the 
microenvironment of proliferation centres induce NF-jB 
transcriptional activity to up-regulate chemokines, cell cycle 
regulators and anti-apoptotic proteins that further increase the 
resistance of CLL cells to apoptosis. Similarly, STAT3 
regulates the expression of anti-apoptotic, pro-proliferative and 
immune response genes, therefore playing a role in the 
interaction between cancer cells and their microenvironment 
(Grivennikov & Karin, 2010). Although this supports their 
importance in the cellular response to dinaciclib, further 
experiments will be needed to confirm this.  
Dinaciclib also has an inhibitory effect on anti-apoptotic 
proteins, which is likely to reinforce its induction of CLL cell 
death. Indeed, we observed that MCL1 and BCL-xL levels 
decreased upon dinaciclib treatment. Similar results were 
observed with other CDK inhibitors, such as Seliciclib/R-ros-
covitiine/CYC202 (Hallaert et al, 2007). However, the levels 
of BCL2 showed a variable response in primary cells. Specific 
inhibition of BCL2 greatly enhanced the effects of dinaciclib 
(see Fig 4), which suggests that the anti-apoptotic effects of 
BCL2 could provide cellular resistance to dinaciclib in certain 
patients. The downregulation of these and other proteins by 
dinaciclib, including AKT, IjBa and NF-jB, could be due to its 
ability to regulate transcription (Alvi et al, 2005; Natoni et al, 
2011), particularly, the inhibition on CDK9, which tar-gets 
RNA polymerase II activity (Oelgeschl€ager, 2002). Thus, 
repression of transcription has been considered as a mecha-
nism that explains how CDK inhibitors kill cancer cells (Alvi 
et al, 2005; Natoni et al, 2011).  
Dinaciclib is being tested in clinical trials, alone or in 
combination with drugs like rituximab, especially in the con-
text of relapsed or refractory CLL (Fabre et al, 2014; Flynn et 
al, 2015; Blachly et al, 2016). Our results suggest that 
dinaciclib is unlikely to be a useful monotherapy, due to its 
toxicity and the existence of a percentage of refractory cells, 
but it could be combined with other specific small molecular 
inhibitors, like ibrutinib or ABT-199, and be highly effective 
at nanomolar concentrations. Ibrutinib is an irreversible inhi-
bitor of Bruton tyrosine kinase (BTK), which has shown 
 
 
 
robust clinical activity in CLL (Herman et al, 2011; Byrd et 
al, 2013) and has been approved by the US Food and Drug 
Administration (FDA) for the treatment of CLL. Resis-tance 
to ibrutinib monotherapy in CLL patients appears to be due to 
the mutation of cysteine to serine at position 481 of BTK 
(Woyach et al, 2014). According to our data, combi-nation 
with low concentrations of dinaciclib could potentiate the 
effects of ibrutinib and reduce chemoresistance. Similarly, 
ABT-199, a third-generation BCL2 inhibitor, has shown clin-
ical potential in a wide variety of haematological malignan-
cies, including CLL (Scarfo & Ghia, 2013; Souers et al, 2013; 
Pan et al, 2014). However, it selectively targets BCL2 but not 
MCL1. This may confer resistance to this drug, since MCL1 
can compensate for the loss of BCL2 function (Moulding et 
al, 2000). Consistent with this, down-regulation of MCL1 
increases the lethality of the BCL2 inhibitor ABT-737 in 
human leukaemia cells (Chen et al, 2007). We showed that 
the capacity of ABT-199 to induce apoptosis in CLL cells was 
improved by combining it with dinaciclib, perhaps mediated 
by its effects on MCL1. This supports the hypothe-sis that 
dinaciclib could sensitize CLL cells to BCL2 inhibi-tors and 
enhance its therapeutic effects.  
In summary, our data proposes a mechanistic explanation 
for the effects of dinaciclib on CLL cell survival and support 
the idea that using CDK inhibitors in combination with other 
specific inhibitors could improve current treatments of CLL. 
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version of this article:  
Fig S1. (A) Same as Fig 1A, using Eskol and JVM3 cells.  
(B) Viability of unmutated and mutated CLL cells co-cul-  
tured with NTL/CD154/IL-4 for 48 h, before being treated 
with 0.1 or 0.01 µmol/l of different drugs for 48 h, as 
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measured by MTS assay. Patient cells used: P11, P4, P5, P7, 
P8, P15, P20, P23, P28, P29, P31, P32.  
Fig S2. (A) Same as Fig 3A, using 0.01 lmol/l dinaciclib.  
(B) Western blot of MEC-1 cells treated with DMSO ( ) or 0.1 
lmol/l dinaciclib (+) for the indicated hours, showing levels of 
different phosphorylated proteins. (C) Same as Fige 3B, using 
ESKOL and JVM3. 
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Table S1. Relevant clinical information for the primary 
CLL samples used. #: patient number used in the text; nd: not 
determined; U: unmutated; M: mutated.  
Table S2. List of patient cells most sensitive and less sensi-
tive to dinaciclib, according to the results shown in Fig 1F. 
Patient number, sex (M/F) and cytogenetics are included. 
 
 
References 
 
Alvi, A.J., Austen, B., Weston, V.J., Fegan, C., 
Maccallum, D., Gianella-Borradori, A., Lane, 
D.P., Hubank, M., Powell, J.E., Wei, W., Taylor, 
A.M., Moss, P.A. & Stankovic, T. (2005) A novel 
CDK inhibitor, CYC202 (R-roscovitine), over-
comes the defect in p53-dependent apoptosis in 
B-CLL by down-regulation of genes involved in 
transcription regulation and survival. Blood, 105, 
4484–4491.  
Blachly, J.S. & Byrd, J.C. (2013) Emerging drug 
profile: cyclin-dependent kinase inhibitors. Leu-
kaemia & Lymphoma, 54, 2133–2143.  
Blachly, J.S., Byrd, J.C. & Grever, M. (2016) 
Cyclin-dependent kinase inhibitors for the treat-
ment of chronic lymphocytic leukemia. 
Seminars in Oncology, 43, 265–273.  
Bose,  P.,  Simmons,  G.L.  &  Grant,  S.  (2013) 
Cyclin-dependent  kinase  inhibitor  therapy  for 
hematologic  malignancies.  Expert  Opinion  on  
Investigational Drugs, 22, 723–738.  
Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., 
Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., 
Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., 
Heerema, N.A., Johnson, A.J., Suk-buntherng, J., 
Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., 
James, D.F. & O’Brien, S. (2013) Targeting  BTK  
with  Ibrutinib  in  relapsed chronic  lymphocytic  
leukemia.  New  England  
Journal of Medicine, 369, 32–42.  
Chen, S., Dai, Y., Harada, H., Dent, P. & Grant, S. 
(2007) Mcl-1 down-regulation potentiates ABT-
737 lethality by cooperatively inducing Bak acti-
vation and Bax translocation. Cancer Research, 
67, 782–791.  
Chen, X.X., Xie, F.F., Zhu, X.J., Lin, F., Pan, S.S., 
Gong, L.H., Qiu, J.G., Zhang, W.J., Jiang, Q.W., 
Mei, X.L., Xue, Y.Q., Qin, W.M., Shi, Z. & Yan, 
X.J. (2015) Cyclin-dependent kinase inhibitor 
dinaciclib potently synergizes with cisplatin in 
preclinical models of ovarian cancer. 
Oncotarget, 6, 14926–14939.  
Chiorazzi, N., Rai, K.R. & Ferrarini, M. (2005) 
Chronic lymphocytic leukemia. New England  
Journal of Medicine, 352, 804–815.  
Cosimo, E., McCaig, A.M., Carter-Brzezinski, L.J., 
Wheadon, H., Leach, M.T., le Ster, K., Berthou, C., 
Durieu, E., Oumata, N., Galons, H., Meijer,  
L. & Michie, A.M. (2013) Inhibition of NF-jB-
mediated signaling by the cyclin-dependent 
kinase inhibitor CR8 overcomes prosurvival 
stimuli to induce apoptosis in chronic lympho-
cytic leukemia cells. Clinical Cancer Research, 
19, 2393–2405. 
 
 
Cunı, S., Perez-Aciego, P., Perez-Chacon, G., Var-
gas, J.A., Sanchez, A., Martın-Saavedra, F.M., 
Ballester, S., Garcıa-Marco, J., Jorda, J. & 
Durantez, A. (2004) A sustained activation of 
PI3K/NF-kappaB pathway is critical for the sur-
vival of chronic lymphocytic leukemia B cells. 
Leukemia, 18, 1391–1400.  
Danilov, A.V. (2013) Targeted therapy in chronic 
lymphocytic leukemia: past, present, and future. 
Clinical Therapeutics, 35, 1258–1270.  
Dyer, M.J., Vogler, M., Samuel, J., Jayne, S., Wag-
ner, S., Pritchard, C. & Macip, S. (2013) Preci-
sion medicines for B-cell leukaemias and 
lymphomas; progress and potential pitfalls. Bri-
tish Journal of Haematology, 160, 725–733.  
Fabre, C., Gobbi, M., Ezzili, C., Zoubir, M., Sablin, 
M.P., Small, K., Im, E., Shinwari, N., Zhang, D., 
Zhou, H. & le Tourneau, C. (2014) Clinical study 
of the novel cyclin-dependent kinase inhi-bitor 
dinaciclib in combination with rituximab in 
relapsed/refractory chronic lymphocytic leu-
kemia patients. Cancer Chemotherapy and 
Phar-macology, 74, 1057–1064.  
Feldman, R.I., Wu, J.M., Polokoff, M.A., 
Kochanny, M.J., Dinter, H., Zhu, D., Biroc, S.L., 
Alicke, B., Bryant, J., Yuan, S., Buckman, B.O., 
Lentz, D., Ferrer, M., Whitlow, M., Adler, M., 
Finster, S., Chang, Z. & Arnaiz, D.O. (2005) 
Novel small molecule inhibitors of 3-phosphoi-
nositide-dependent kinase-1. Journal of 
Biological Chemistry, 280, 19867–19874.  
Flynn, J., Jones, J., Johnson, A.J., Andritsos, L., 
Maddocks, K., Jaglowski, S., Hessler, J., Grever, 
M.R., Im, E., Zhou, H., Zhu, Y., Zhang, D., 
Small, K., Bannerji, R. & Byrd, J.C. (2015) 
Dinaciclib is a novel cyclin-dependent kinase 
inhibitor with significant clinical activity in 
relapsed and refractory chronic lymphocytic leu-
kemia. Leukemia, 29, 1524–1529.  
Fu, W., Ma, L., Chu, B., Wang, X., Bui, M.M., 
Gemmer, J., Altiok, S. & Pledger, W.J. (2011) 
The cyclin-dependent kinase inhibitor SCH 
727965 (dinacliclib) induces the apoptosis of 
osteosarcoma cells. Molecular Cancer 
Therapeu-tics, 10, 1018–1027.  
Furman, R.R., Asgary, Z., Mascarenhas, J.O., Liou, 
H.C. & Schattner, E.J. (2000) Modulation of NF-
kappa B activity and apoptosis in chronic 
lymphocytic leukemia B cells. The Journal of 
Immunology, 164, 2200–2206.  
Gregory, G.P., Hogg, S.J., Kats, L.M., Vidacs, E., 
Baker,  A.J.,  Gilan,  O.,  Lefebure,  M.,  Martin, 
B.P., Dawson, M.A., Johnstone, R.W. & Shortt, J. 
(2015) CDK9 inhibition by dinaciclib potently 
suppresses Mcl-1 to induce durable apoptotic 
 
 
responses in aggressive MYC-driven B-cell lym-
phoma in vivo. Leukemia, 29, 1437–1441.  
Grivennikov, S.I. & Karin, M. (2010) Dangerous 
liaisons: STAT3 and NF-kappaB collaboration 
and crosstalk in cancer. Cytokine & Growth 
Fac-tor Reviews, 21, 11–19.  
Guo, N. & Peng, Z. (2013) MG132, a proteasome 
inhibitor,  induces  apoptosis  in  tumor  cells. Asia-
Pacific Journal of Clinical Oncology, 9, 6–11. ten 
Hacken, E. & Burger, J.A. (2014) Molecular 
pathways:  targeting  the  microenvironment  in 
chronic lymphocytic leukemia–focus on the B-cell 
receptor. Clinical Cancer Research, 20, 548–  
556.  
Hallaert, D.Y., Spijker, R., Jak, M., Derks, I.A., Alves, 
N.L., Wensveen, F.M., de Boer, J.P., de Jong, D., 
Green, S.R., van Oers, M.H. & Eldering, E. (2007) 
Crosstalk among Bcl-2 family members in B-CLL: 
seliciclib acts via the Mcl-1/Noxa axis and gradual 
exhaustion of Bcl-2 protection. Cell Death and 
Differentiation, 14, 1958–1967.  
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-
Cappio, F., Dighiero, G., Dohner, H., Hillmen, 
P., Keating, M. J., Montserrat, E., Rai, K. R. & 
Kipps, T. J. & International Workshop On 
Chronic Lymphocytic Leukemia. 2008. Guideli-
nes for the diagnosis and treatment of chronic 
lymphocytic leukemia: a report from the Inter-
national Workshop on Chronic Lymphocytic 
Leukemia updating the National Cancer Insti-
tute-Working Group 1996 guidelines. Blood, 
111, 5446–5456.  
Hazan-Halevy, I., Harris, D., Liu, Z., Liu, J., Li, P., 
Chen, X., Shanker, S., Ferrajoli, A., Keating, M.J.  
& Estrov, Z. (2010) STAT3 is constitutively 
phosphorylated on serine 727 residues, binds 
DNA, and activates transcription in CLL cells.  
Blood, 115, 2852–2863.  
Herman, S.E., Gordon, A.L., Hertlein, E., Rama-
nunni, A., Zhang, X., Jaglowski, S., Flynn, J., 
Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., 
Johnson, A.J. & Byrd, J.C. (2011) Bruton tyro-
sine kinase represents a promising therapeutic 
target for treatment of chronic lymphocytic leu-
kemia and is effectively targeted by PCI-32765. 
Blood, 117, 6287–6296.  
Hewamana, S., Alghazal, S., Lin, T.T., Clement, 
M., Jenkins, C., Guzman, M.L., Jordan, C.T., 
Neelakantan,  S.,  Crooks,  P.A.,  Burnett,  A.K., 
Pratt, G., Fegan, C., Rowntree, C., Brennan, P.  
& Pepper, C. (2008) The NF-kappaB subunit Rel 
A is associated with in vitro survival and clinical 
disease progression in chronic lympho-cytic 
leukemia and represents a promising thera-peutic 
target. Blood, 111, 4681–4689. 
 
 
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 9 
Y. Chen et al 
 
Johnson, A.J., Yeh, Y.Y., Smith, L.L., Wagner, 
A.J., Hessler, J., Gupta, S., Flynn, J., Jones, J., 
Zhang, X., Bannerji, R., Grever, M.R. & Byrd, 
J.C. (2012) The novel cyclin-dependent kinase 
inhi-bitor dinaciclib (SCH727965) promotes 
apopto-sis and abrogates microenvironmental 
cytokine protection in chronic lymphocytic 
leukemia cells. Leukemia, 26, 2554–2557.  
Kawauchi, K., Ogasawara, T. & Yasuyama, M. 
(2002) Activation of extracellular signal-regu-
lated kinase through B-cell antigen receptor in B-
cell chronic lymphocytic leukemia. Interna-
tional Journal of Hematology, 75, 508–513.  
Kitada, S., Andersen, J., Akar, S., Zapata, J.M.,  
Takayama, S., Krajewski, S., Wang, H.G., Zhang, X., 
Bullrich, F., Croce, C.M., Rai, K., Hines, J. & Reed, 
J.C. (1998) Expression of apoptosis-regu-lating 
proteins in chronic lymphocytic leukemia: 
correlations with In vitro and In vivo chemore-
sponses. Blood, 91, 3379–3389.  
Kumar, S. K., Laplant, B., Chng, W. J., Zonder, J., 
Callander, N., Fonseca, R., Fruth, B., Roy, V., 
Erlichman, C., Stewart, A. K. & Consortium, M. 
P. (2015) Dinaciclib, a novel CDK inhibitor, 
demonstrates encouraging single-agent activity in 
patients with relapsed multiple myeloma. Blood, 
125, 443–448.  
Liu, Z., Hazan-Halevy, I., Harris, D.M., Li, P., Fer-
rajoli, A., Faderl, S., Keating, M.J. & Estrov, Z. 
(2011) STAT-3 activates NF-kappaB in chronic 
lymphocytic leukemia cells. Molecular Cancer 
Research, 9, 507–515.  
Malumbres, M. & Barbacid, M. (2009) Cell cycle, 
CDKs and cancer: a changing paradigm. Nature 
Reviews Cancer, 9, 153–166.  
Meads, M.B., Hazlehurst, L.A. & Dalton, W.S. (2008) 
The bone marrow microenvironment as a tumor 
sanctuary and contributor to drug resis-tance. 
Clinical Cancer Research, 14, 2519–2526.  
Mittal, A.K., Chaturvedi, N.K., Rai, K.J., Gilling-
Cutucache, C.E., Nordgren, T.M., Moragues, M., 
Lu, R., Opavsky, R., Bociek, G.R., 
Weisenburger, D.D., Iqbal, J. & Joshi, S.S. 
(2014) Chronic lym-phocytic leukemia cells in a 
lymph node microenvironment depict molecular 
signature associated with an aggressive disease. 
Molecular Medicine, 20, 290–301.  
Moulding, D.A., Giles, R.V., Spiller, D.G., White, 
M.R., Tidd, D.M. & Edwards, S.W. (2000) 
Apoptosis is rapidly triggered by antisense 
depletion of MCL-1 in differentiating U937 cells. 
Blood, 96, 1756–1763.  
Muzio, M., Apollonio, B., Scielzo, C., Frenquelli, 
M., Vandoni, I., Boussiotis, V., Caligaris-Cappio, 
F. & Ghia, P. (2008) Constitutive activation of 
distinct BCR-signaling pathways in a subset of 
CLL patients: a molecular signature of anergy. 
Blood, 112, 188–195.  
Natoni, A., Murillo, L.S., Kliszczak, A.E., Cather-
wood, M.A., Montagnoli, A., Samali, A., 
O’Dwyer, M. & Santocanale, C. (2011) Mecha-
nisms of action of a dual Cdc7/Cdk9 kinase 
inhibitor against quiescent and proliferating CLL 
cells. Molecular Cancer Therapeutics, 10, 
1624–1634. 
 
 
 
Nemunaitis, J.J., Small, K.A., Kirschmeier, P., 
Zhang, D., Zhu, Y., Jou, Y.M., Statkevich, P., 
Yao, S.L. & Bannerji, R. (2013) A first-in-
human, phase 1, dose-escalation study of dinaci-
clib, a novel cyclin-dependent kinase inhibitor, 
administered weekly in subjects with advanced 
malignancies. Journal of Translational 
Medicine, 11, 259. 
 
Oelgeschl€ager, T. (2002) Regulation of RNA 
poly-merase II activity by CTD phosphorylation 
and cell cycle control. Journal of Cellular 
Physiology, 190, 160–169.  
Ogasawara, T., Yasuyama, M. & Kawauchi, K. 
(2003) Constitutive activation of extracellular 
signal-regulated kinase and p38 mitogen-acti-
vated protein kinase in B-cell lymphoprolifera-
tive disorders. International Journal of 
Hematology, 77, 364–370.  
Paiva, C., Godbersen, J.C., Soderquist, R.S., Row-
land, T., Kilmarx, S., Spurgeon, S.E., Brown, 
J.R., Srinivasa, S.P. & Danilov, A.V. (2015) 
Cyclin-dependent kinase inhibitor P1446A 
induces apoptosis in a JNK/p38 MAPK-depen-
dent manner in chronic lymphocytic leukemia B-
cells. PLoS ONE, 10, e0143685.  
Pan, R., Hogdal, L.J., Benito, J.M., Bucci, D., Han, 
L., Borthakur, G., Cortes, J., Deangelo, D.J.,  
Debose, L., Mu, H., Dohner,€ H., Gaidzik, V.I., 
Galinsky, I., Golfman, L.S., Haferlach, T., Haru-
tyunyan, K.G., Hu, J., Leverson, J.D., Marcucci,  
G., Muschen,€ M., Newman, R., Park, E., 
Ruvolo, P.P., Ruvolo, V., Ryan, J., Schindela, S., 
Zwei-dler-Mckay, P., Stone, R.M., Kantarjian, 
H., Andreeff, M., Konopleva, M. & Letai, A.G. 
(2014) Selective BCL-2 inhibition by ABT-199 
causes on-target cell death in acute myeloid leu-
kemia. Cancer Discovery, 4, 362–375.  
Pardanani, A., Hood, J., Lasho, T., Levine, R.L., 
Martin,  M.B.,  Noronha,  G.,  Finke,  C.,  Mak, 
C.C., Mesa, R., Zhu, H., Soll, R., Gilliland, D.G.  
& Tefferi, A. (2007) TG101209, a small molecule 
JAK2-selective kinase inhibitor potently inhibits 
 
myeloproliferative disorder-associated 
JAK2V617F and MPLW515L/K mutations. Leu-
kemia, 21, 1658–1668.  
Parrish, A. B., Freel, C. D. & Kornbluth, S. 2013. 
Cellular mechanisms controlling caspase activa-tion 
and function. Cold Spring Harbor Perspec-  
tives in Biology, 5, 1–24.  
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prab-
havalkar, D., Wiswell, D., Seghezzi, W., Paruch, 
K., Dwyer, M.P., Doll, R., Nomeir, A., Windsor, 
W., Fischmann, T., Wang, Y., Oft, M., Chen, T., 
Kirschmeier, P. & Lees, E.M. (2010) Dinaciclib 
(SCH 727965), a novel and potent cyclin-depen-
dent kinase inhibitor. Molecular Cancer Thera-
peutics, 9, 2344–2353.  
Paruch, K., Dwyer, M.P., Alvarez, C., Brown, C., 
Chan, T.Y., Doll, R.J., Keertikar, K., Knutson, C.,  
McKittrick,  B.,  Rivera,  J.,  Rossman,  R., Tucker, 
G., Fischmann, T., Hruza, A., Madison, V., Nomeir, 
A.A., Wang, Y., Kirschmeier, P., Lees, E., Parry, 
D., Sgambellone, N., Seghezzi, W., Schultz, L., 
Shanahan, F., Wiswell, D., Xu, X., Zhou, Q., James, 
R.A., Paradkar, V.M., Park, 
 
 
 
H., Rokosz, L.R., Stauffer, T.M. & Guzi, T.J. 
(2010) Discovery of Dinaciclib (SCH 727965): a 
potent and selective inhibitor of cyclin-depen-
dent kinases. ACS Medicinal Chemistry 
Letters, 1, 204–208.  
Pepper, C., Lin, T.T., Pratt, G., Hewamana, S., 
Brennan, P., Hiller, L., Hills, R., Ward, R., Star-
czynski, J., Austen, B., Hooper, L., Stankovic, T.  
& Fegan, C. (2008) Mcl-1 expression has in vitro 
and in vivo significance in chronic lymphocytic 
leukemia and is associated with other poor prog-
nostic markers. Blood, 112, 3807–3817.  
Pickering, B.M., de Mel, S., Lee, M., Howell, M., 
Habens, F., Dallman, C.L., Neville, L.A., Potter, 
K.N., Mann, J., Mann, D.A., Johnson, P.W., 
Stevenson, F.K. & Packham, G. (2007) Pharma-
cological inhibitors of NF-kappaB accelerate 
apoptosis in chronic lymphocytic leukaemia cells. 
Oncogene, 26, 1166–1177.  
Reikvam, H., Nepstad, I., Sulen, A., Gjertsen, B.T., 
Hatfield, K.J. & Bruserud, Ø. (2013) Increased 
antileukemic effects in human acute myeloid 
leukemia by combining HSP70 and HSP90 inhi-
bitors. Expert Opinion on Investigational 
Drugs, 22, 551–563.  
Ringshausen, I., Schneller, F., Bogner, C., Hipp, S., 
Duyster, J., Peschel, C. & Decker, T. (2002) 
Constitutively activated phosphatidylinositol-3 
kinase (PI-3K) is involved in the defect of apop-
tosis in B-CLL: association with protein kinase 
Cdelta. Blood, 100, 3741–3748.  
Rozovski, U., Wu, J.Y., Harris, D.M., Liu, Z., Li, 
P., Hazan-Halevy, I., Ferrajoli, A., Burger, J.A., 
O’Brien, S., Jain, N., Verstovsek, S., Wierda, 
W.G., Keating, M.J. & Estrov, Z. (2014) Stimu-
lation of the B-cell receptor activates the JAK2/ 
STAT3 signaling pathway in chronic lympho-
cytic leukemia cells. Blood, 123, 3797–3802.  
Sainz-Perez, A., Gary-Gouy, H., Portier, A., Davi, 
F., Merle-Beral, H., Galanaud, P. & Dalloul, A. 
(2006) High Mda-7 expression promotes malig-
nant cell survival and p38 MAP kinase activa-
tion in chronic lymphocytic leukemia. 
Leukemia, 20, 498–504.  
Samuel, J., Macip, S. & Dyer, M.J. (2014) Efficacy 
of vemurafenib in hairy-cell leukemia. New 
Eng-land Journal of Medicine, 370, 286–288.  
Scarfo, L. & Ghia, P. (2013) Reprogramming cell 
death: BCL2 family inhibition in hematological 
malignancies. Immunology Letters, 155, 36–39.  
Souers, A.J., Leverson, J.D., Boghaert, E.R., Ackler, 
S.L., Catron, N.D., Chen, J., Dayton, B.D., Ding, H., 
Enschede, S.H., Fairbrother, W.J., Huang, D.C., 
Hymowitz, S.G., Jin, S., Khaw, S.L., Kovar, P.J., 
Lam, L.T., Lee, J., Maecker, H.L., Marsh, K.C., 
Mason, K.D., Mitten, M.J., Nimmer, P.M., 
Oleksijew, A., Park, C.H., Park, C.M., Phillips, D.C., 
Roberts, A.W., Sampath, D., Seymour, J.F., Smith, 
M.L., Sullivan, G.M., Tahir, S.K., Tse, C., Wendt, 
M.D., Xiao, Y., Xue, J.C., Zhang, H., 
Humerickhouse, R.A., Rosenberg, S.H. & Elmore, 
S.W. (2013) ABT-199, a potent and selective BCL-2 
inhibitor, achieves antitu-mor activity while sparing 
platelets. Nature Med-icine, 19, 202–208. 
 
 
10 ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 
Effects of Dinaciclib on Pro-Survival Signals in CLL 
 
Stacchini, A., Aragno, M., Vallario, A., Alfarano, 
A., Circosta, P., Gottardi, D., Faldella, A., Rege-
Cambrin, G., Thunberg, U., Nilsson, K. & Cali-
garis-Cappio, F. (1999) MEC1 and MEC2: two 
new cell lines derived from B-chronic lympho-
cytic leukaemia in prolymphocytoid transforma-
tion. Leukemia Research, 23, 127–136.  
Sylvan, S.E., Skribek, H., Norin, S., Muhari, O., 
Osterborg, A. & Szekely, L. (2016) Sensitivity of 
chronic lymphocytic leukemia cells to small 
targeted therapeutic molecules: an in vitro 
comparative study. Experimental Hematology, 
44, e1.  
Varadarajan, S., Poornima, P., Milani, M., Gowda, 
K., Amin, S., Wang, H.G. & Cohen, G.M. 
 
 
(2015) Maritoclax and dinaciclib inhibit MCL-1 
activity and induce apoptosis in both a MCL-1-
dependent and -independent manner. Oncotar-
get, 6, 12668–12681.  
Vogler, M., Butterworth, M., Majid, A., Walewska, 
R.J., Sun, X.M., Dyer, M.J. & Cohen, G.M. 
(2009) Concurrent up-regulation of BCL-XL and 
BCL2A1 induces approximately 1000-fold 
resistance to ABT-737 in chronic lymphocytic 
leukemia. Blood, 113, 4403–4413.  
Willimott, S., Baou, M., Huf, S. & Wagner, S.D. 
(2007a) Separate cell culture conditions to pro-
mote proliferation or quiescent cell survival in 
chronic lymphocytic leukemia. Leukaemia & 
Lymphoma, 48, 1647–1650. 
 
 
Willimott, S., Baou, M., Naresh, K. & Wagner, S.D. 
(2007b) CD154 induces a switch in pro-survival 
Bcl-2 family members in chronic lym-phocytic 
leukaemia. British Journal of Haematol-ogy, 
138, 721–732.  
Woyach,  J.A.,  Furman,  R.R.,  Liu,  T.M.,  Ozer, 
H.G., Zapatka, M., Ruppert, A.S., Xue, L., Li, D.H., 
Steggerda, S.M., Versele, M., Dave, S.S., Zhang, J., 
Yilmaz, A.S., Jaglowski, S.M., Blum, K.A., 
Lozanski, A., Lozanski, G., James, D.F., Barrientos,  
J.C.,  Lichter,  P.,  Stilgenbauer,  S., Buggy, J.J., 
Chang, B.Y., Johnson, A.J. & Byrd, J.C. (2014) 
Resistance mechanisms for the Bru-ton’s  tyrosine 
kinase  inhibitor  ibrutinib.  New  
England Journal of Medicine, 370, 2286–2294. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 11 
 
correspondence 
Paradoxical activation of alternative pro-survival pathways 
determines resistance to MEK inhibitors in chronic lymphocytic 
leukaemia  
 
 
 
 
In order to explore novel therapeutic opportunities for B-cell 
malignancies, we evaluated the effects of MEK inhibitors 
(MEKi) on chronic lymphocytic leukaemia (CLL). We found 
that none had a significant effect on CLL viability, despite 
inhibiting signalling. Paradoxically, MEKi promoted the 
accumulation of active MEK and CRAF, reduced the expres-
sion of negative regulators of the pathway and augmented 
AKT signalling. Combining MEKi and phosphoinositide 3-
kinase (PI3K) inhibitors antagonized this effect and induced 
cell death. We propose that MEKi-mediated activa-tion of pro-
survival pathways explains their low toxicity in CLL and that 
inhibition of both RAF/MEK/ERK and PI3K/ AKT signalling 
could overcome single-agent resistance.  
The RAF/MEK/ERK signalling cascade is activated in 
nearly half of CLL patients, suggesting a pathogenic role 
(Muzio et al, 2008). Selective inhibitors have been developed, 
including MEK1/2 inhibitors (MEKi) that are being clinically  
 
 
 
 
 
 
assessed as a monotherapy or in combination. However, MEKi 
have a lower efficiency in cancers not driven by mutant BRAF 
or KRAS, due to resistance mechanisms. This has limited the 
clinical use of these compounds.  
To test the effects of blocking the RAF/MEK/ERK pathway 
in CLL, we used different MEKi (U0126, PD0325901, 
selumetinib and trametinib) on the MEC-1 cell line, often used 
as a model for CLL, in which we observed increased 
RAF/MEK/ERK signalling (Chen et al, 2016). We used sora-
fenib (pan-RAF inhibitor) and dabrafenib (BRAF inhibitor) 
for comparison. Materials and methods are detailed in the 
Supplementary material. MEKi did not affect the viability (Fig 
1A), survival (Figure S1A), cell cycle profile (Figure S1B), 
Mcl-1 levels or PARP cleavage (Figure S1C) in MEC-1, and 
only very high concentrations of sorafenib decreased Mcl-1 
expression, cleaved PARP and induced death in MEC-1 (Fig 
1A, S1A–C). Similar results were observed in JVM3, a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Inhibition of MEK does not affect CLL cell survival. (A) Percentage cell viability of MEC-1 cells at 48 h after treatment with 0 to 10 lM of 
various inhibitors, as measured by an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. 
Experiments were performed in triplicate and repeated at least twice. Graphics show mean values and error bars represent standard deviation, as in 
all the other panels of this figure. (B) Percentage cell viability of CLL patient cells cultured for 24 h in the presence of 10 ng/ml IL4/CD154, 48 h 
after treatment with the same inhibitors. Eight to 19 different samples were tested for each inhibitor, and experiments were performed in triplicate. 
(C) Representative Western blots using lysates of MEC-1 treated with different concentrations of MEK or RAF inhibitors for 16 h. Pro-tein levels of 
ERK, phospho-ERK (P-ERK), MEK and phospho-MEK (P-MEK) were detected with specific antibodies. (D) Representative Western blots using 
lysates of primary cells obtained patients. Cells were cultured as described and treated with different concentrations of selumetinib, trametinib or 
sorafenib for 16 h. The total and phosphorylated levels of ERK and MEK were measured with specific antibodies. 
ª 2017 John Wiley & Sons Ltd, British Journal of Haematology doi: 10.1111/bjh.14880  
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Fig 2. (A) Co-immunoprecipitation measuring the levels of BRAF-CRAF dimerization in MEC-1 cells treated with 5 lmol/l selumetinib, 0 1 lmol/l 
trametinib or 0 5 lmol/l sorafenib for 16 h. Cell lysates were incubated with BRAF or CRAF antibodies, following protein A-Sephar-ose beads 
precipitation. Precipitated BRAF and CRAF proteins were measured by Western blotting. (B) Representative Western blots using MEC-1 cells 
treated with different concentrations of selumetinib or trametinib for 16 h. Detection of subject P-BRAF (Ser445), P-CRAF (Ser338) and P-CRAF 
(Ser289/296/301) was done using specific antibodies. (C) Top Left: mRNA expression of SPRY2, SPRED1 and SPRED2, which encode members 
of the SPRY family of proteins that have been reported to be negative regulators of RAF/MEK/ERK signalling, in MEC-1 cells treated with different 
concentrations of selumitinib for 16 h. The expression of each of these genes was normalized to GAPDH and values are shown as relative to 
untreated cells. Experiments were performed in triplicate and repeated at least 3 times. Top right: mRNA expression of SPRY2, SPRED1 and 
SPRED2 in MEC-1 cells treated with different concentrations of trametinib for 16 h. Bottom left: mRNA expression of DUSP4/5/6 in MEC-1 cells 
treated with different concentrations of selumitinib for 16 h. Bottom right: mRNA expression of DUSP4/5/6 in MEC-1 cells trea-ted with different 
concentrations of trametinib for 16 h. (D) Representative Western blots using lysates of MEC-1 cells treated with different con-centrations of 
selumetinib or trametinib for 16 h. Total and Ser473phosphorylated (active) levels of AKT were measured. (E) Representative Western blots using 
lysates of MEC-1 treated with different concentrations of CUDC907 (CUDC) alone (+dimethyl sulphoxide, DMSO) or in combination with 0 01 
lmol/l trametinib or 10 lmol/l selumetinib for 16 h. Total and phosphorylated levels of AKT and ERK were measured using specific antibodies. (F) 
Top: Cell cycle profiles of MEC-1 cells treated with different concentrations of selumetinib or CUDC907 for 48 h, as measured by propidium iodide 
staining and fluorescence-activated cell sorting analysis. Bottom: Cell cycle profiles of MEC-1 cells treated with a combined treatment of 
selumetinib (0 1, 1 or 10 lmol/l) and CUDC907 (0 005, 0 01 or 0 1 lmol/l) for 48 h. SubG1 events are indicative of the percentage of cell death. 
Results show average of 3 independent experiments and error bars represent standard deviation. 
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B-prolymphocytic leukaemia cell line (Figure S1D). In con-
trast, the viability of SIG-M5, an acute myeloid leukaemia cell 
line with a BRAF mutation, was reduced (Figure S1D), 
consistent with the known sensitivity of BRAF-driven malig-
nancies to RAF/MEK/ERK inhibition. In primary cells stimu-
lated with CD40 ligand (CD40L)/interleukin 4 (IL4) to mimic 
the microenvironment of proliferation centres, MEKi did not 
reduce viability either (Fig 1B). This suggests that MEKi do 
not affect survival of CLL cells at pharmacologically relevant 
doses.  
We found that the downstream phosphorylation of ERK (on 
Thr202 and Tyr204) in MEC-1 was abolished by MEKi, as 
expected (Fig 1C). However, MEKi induced Ser218/222-
phosphorylated MEK, suggesting an upstream reactivation of 
the pathway. This was also the case in patient cells stimulated 
with CD40L/IL4 (Fig 1D) or co-cultured with mouse fibrob-
last L cells (NTL)/CD154/IL4 (Figure S2A). Of note, sorafe-
nib and dabrafenib reduced the phosphorylation of both MEK 
and ERK (Fig 1C and D).  
BRAF-CRAF dimerization reactivates ERK signalling in 
BRAF-wild type cells treated with BRAF-specific inhibitors. 
Moreover, BRAF-CRAF dimerization is required for RAF 
activation. Thus, we reasoned that MEKi-triggered MEK 
phosphorylation could be due to RAF reactivation. However, 
MEKi did not promote dimer formation, although sorafenib 
was able to enhance it (Fig 2A). MEKi treatment did not 
change the activating phosphorylation of BRAF (Ser445), but 
it either increased phosphorylated Ser338 in CRAF, which is 
related to activation, and/or decreased its inhibitory Ser289/ 
296/301 phosphorylation (Fig 2B). This is consistent with 
ERK being inhibited in response to MEKi. MEKi did not 
change the expression of protein phosphatase 2A (PP2A), 
which regulates RAF/MEK/ERK by dephosphorylating CRAF 
(Figure S2B). This shows that MEKi reactivate CRAF, which 
could mediate the accumulation of MEK. We next examined 
the effects of MEKi on negative regulators of the pathway. We 
found that MEKi decreased SPRED1/2, SPRY2 and 
DUSP4/5/6 in a dose-dependent manner (Fig 2C). Downreg-
ulation of all these modulators could also contribute to the 
reactivation of upstream RAF/MEK/ERK signalling.  
We also found that selumetinib activated AKT (Fig 2D), as 
did trametinib, although the effect was reversed at higher 
concentrations. This suggested that AKT could contribute to 
MEKi resistance. To test this, we used CUDC907, which 
inhibits histone deacetylases and PI3K. The combination of 
MEKi and CUDC907 suppressed ERK and AKT signalling, as 
expected (Fig 2E). Low concentrations of CUDC907 did not 
induce cell death in MEC-1 (Fig 2F), but when combined with 
non-toxic concentrations of selumetinib, cell death increased to 
40–50%. This shows that a non-lethal suppres-sion of PI3K 
turns MEK inhibition into apoptosis in CLL. This was 
confirmed with trametinib and idelalisib, a specific PI3K d 
inhibitor (Figure S2C). The effect was not observed when two 
RAF/MEK/ERK inhibitors were combined (Figure S2D). 
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We propose that MEKi induce upstream RAF/MEK/ERK 
signalling in CLL by reactivating RAF through downregula-
tion of SPRY and DUSP proteins, leading to phosphorylation 
of CRAF. This results in activation of pro-survival pathways, 
including AKT, and drug resistance. Precision medicines have 
changed the prognosis of blood malignancies but their use is 
hampered by resistance, hence the need to find parameters that 
allow the stratification of patients (Dyer et al, 2013). We 
propose that understanding ERK-dependent signalling feed-
back is important for designing new CLL therapies. The use of 
MEKi as single agents should be discouraged because the 
activation of pro-survival signals may compensate the effect. 
Combination therapies of MEKi with PI3K inhibitors could, 
instead,provide a novel therapeutic strategy. 
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Fig S1. (A) Induction of cell death in the same cells as Fig 
1A, as measured by PI staining and FACS analysis. 
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Graphics show percentage of non-permeabilised cells positive 
for PI fluorescence (dead). (B) Cell cycle profiles of MEC-1 
cells treated with different concentrations of MEKi or sorafe-
nib for 48 h, as measured by PI staining and FACS analysis.  
(C) Representative Western blots of lysates of MEC-1 treated 
with different concentrations of selumetinib, trametinib or 
sorafenib for 16 h. The membranes were probed with anti-
bodies against Mcl-1 (an anti-apoptotic protein) and PARP 
(the cleavage of which is associated with induction of apop-
tosis). b-actin was used as a loading control, as in all the other 
Western blots in this study. (D) Percentage cell viabil-  
ity of JVM3 and SISG-M5 cells 48 h after being treated with 
0–10 lmol/l of various inhibitors, as measured by an MTS 
assay.  
Fig S2. (A) Representative Western blots using lysates of 
CLL patient cells co-cultured with NTL/CD154/IL-4 for 48 h 
before being treated with 0.001 or 1 lmol/l selumetinib or 
trametinib. Total and phosphorylated levels of MEK and ERK 
were measured. (B) mRNA expression of PP2A in MEC-1 
 
 
 
cells treated with different concentrations of selumitinib or 
trametinib for 16 h. The expression of each of these genes was 
normalized to GAPDH and values are shown as relative to 
untreated cells. Experiments were performed in triplicate and 
repeated at least 3 times. (C) Percentage cell viability of MEC-
1 cells 48 h after being treated with trametinib and/or 
idelalisib, as measured by an MTS assay. Although idelalisib 
(first group of bars) or trametinib (black bars) alone do not 
decrease significantly viability, the combination of both 
reduces it up to 60%. Graphics show mean values of three 
experiments and error bars represent standard deviation. (D) 
Top: Cell cycle profiles of MEC-1 cells treated with different 
concentrations of selumetinib or CUDC907 for 48 h, as mea-
sured by PI staining and FACS analysis. Bottom: same, using 
a combined treatment of selumetinib (0.1, 1 or 10 lmol/l) and 
CUDC907 (0.005, 0.01 or 0.1 lmol/l) for the same amount of 
time. SubG1 events are indicative of the percent-age of cell 
death. Results show average of 3 independent experiments and 
error bars represent standard deviation. 
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A3 
ABSTRACT 
 
 
 
NOTCH1 mutations are a poor prognostic factor for Chronic Lymphocytic Leukaemia 
(CLL), associated with resistance to rituximab and increased risk of Richter’s transformation. 
To characterize the role of NOTCH1 mutation in drug sensitivity, we first genotyped exon 34 
(including the 3’-UTR) in 147 CLL patients. We found mutations in 13/106 (12.3%) of a 
random cohort and 13/41 (26.8%) of patients with trisomy 12. The most common mutation, 
seen in 92.3%, was the CT deletion in the PEST domain. We also found two previously 
unreported frame-shift mutations (a 38bp deletion and a nucleotide insertion) in the 
transactivation domain, resulting in loss of the PEST domain. We next treated NOTCH1 
mutated and wild type patient cells with different targeted inhibitors. No differences were 
observed with most of the drugs tested. However, a subgroup of NOTCH1 mutated patients 
showed increased resistance to BCL2 inhibitor venetoclax. To extend our study, we 
compared Rec-1, a malignant B cell line that harbours a NOTCH1 mutation, with wild-type 
cell lines JVM3 and Mec-1. We found that Rec-1 were more sensitive to inhibition of NF-κB 
and γ-secretase. Moreover, combination of ibrutinib with either γ-secretase or BCL2 
inhibitors showed synergy in the mutated cells. Our results show that NOTCH1 mutation in 
CLL defines a subgroup of disease with specific sensitivities to combinations of targeted 
agents that may allow new therapeutic approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
INTRODUCTION 
 
 
 
CLL is a highly heterogeneous disease, in which some patients have an indolent 
course while others suffer aggressive forms with short life expectancy. Heterogeneity is also 
evident at the genetic level 1-4. As the condition progresses, the number of genetic variations 
increases. For example, TP53 mutations are present in 5-10% patients at diagnosis and can 
increase to 60% in advanced cases 1,5,6. IgHV status, stereotyped B-cell receptor subgroups, 
cytogenetic abnormalities as well as a number of recurrent mutations have also been linked to 
prognosis and response to treatments 2,7-9. 
Around 12% of CLL patients harbour NOTCH1 mutations, one of the most recurrent 
in this disease and a poor prognostic factor 4,10. The frequency of mutations increases in 
refractory patients and Richter syndrome (20% and 30% respectively) 11. CLL with 
NOTCH1 mutation progresses faster and is classed to have an intermediate-risk 9,12,13. The 
most common NOTCH1 mutations occur in the PEST domain of the intracellular domain 
(NICD), which targets the protein for degradation 14. Mutations make the domain more 
resistant, leading to accumulation of the NICD. 
 
Notch signalling is a treatment target in a number of cancers, such as breast, brain, 
pancreatic as well as haematological malignancies, in particular T-cell leukaemia 15, but has 
not been considered in the context of CLL. In order to explore this possibility, we sequenced 
a local cohort for NOTCH1 mutations in exon 34, a mutation hotspot, and performed a pre-
clinical evaluation of effectiveness of commercially available small molecule inhibitors. We 
show that NOTCH1 mutations influence the response to drugs, which provides a rationale to 
use them as stratification factors in CLL. 
 
 
 
 
 
 
 
3 
MATERIALS AND METHODS 
 
 
 
Patient samples. A total of 147 patients were used in this project and were categorised into two 
sets. Set #1 included 106 randomly selected patients from the database (Random set) and set #2 
included 41 patients who were known to have clones harbouring Trisomy 12 (Trisomy 12 set). 
Only patients with Trisomy 12 in 50% or more of their tumour population were eligible for the 
second set. The summary of patients’ characteristics is outlined in Table S1. Peripheral blood 
samples were obtained following an informed consent and approval from the Local Research 
Ethics Committee and the Research and Development Office of the University Hospitals of 
Leicester NHS Trust. To prepare B-cell samples for treatment efficacy testing, white blood cells 
were separated from whole blood samples using density separation, as previously described 16. 
White blood cells were then carefully collected and washed in media. The pellet was then 
resuspended and cultured in RPMI-1640 supplemented with 10ng/ml CD40L/IL-4 to mimic the 
microenvironment of proliferation centres and maintain cell survival in vitro 16,17. Cells were 
cultured at 37 °C in an incubator containing 5% CO2. 
 
Cell lines. A NOTCH1 mutated cell line (Rec-1) and two NOTCH1 wild-type cell lines (Mec-1 
and JVM3) were used. All of them were originally derived from B cell malignancies. Cells were 
maintained in complete medium (RPMI-1640 for Rec-1 and JVM3 and IMDM for Mec- 
 
1) with 10% foetal bovine serum 2 mmol/l L-glutamine, 50 u/ml penicillin and 50 mg/ml 
streptomycin. All cell lines were cultured at 37 °C in an incubator containing 5% CO2. 
 
DNA Sequencing. DNA was extracted following treatment with Proteinase K and RNAse. DNA 
samples were PCR amplified and then purified using SureClean. To sequence each sample, two 
sets of primers were used (Table S2). As a result, two overlapping DNA fragments 
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were sequenced, covering around 1,500 base pairs of the exon 34 of NOTCH1 gene, 
including a known mutation hotspot region. Purified PCR products of DNA concentration of 
at least 15 ng/µl and their corresponding primers were send to Beckman Coulter Genomics 
(Genewiz) for Sanger DNA Sequencing. Chromatogram files were then analysed manually 
and the sequence was also analysed using nucleotide BLAST. All samples were compared to 
Homo sapiens notch 1 (NOTCH1) reference sequence (Sequence ID: ref|NG_007458.1). All 
variations were compared to NOTCH1 gene ENSG00000148400, Transcript NOTCH1-001 
on Ensembl database. Expasy translation tool was used to compare amino acid sequences 
based on FASTA sequence. 
 
Cell viability assay. Cell lines and primary cells were treated with inhibitors targeting the 
gamma-secretase complex of the Notch1 protein (RO4929097 and PF-03084014), a BCL2 
inhibitor (ABT199), a NFκB pathway inhibitor (IMD 0354) and a BTK inhibitor (ibrutinib ). 
The suppliers of each inhibitor are listed in the Table S3. All the inhibitors were diluted in 
DMSO. The CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA) was used to estimate cell viability and proliferation after 48 hours of 
treatment, according to the manufacturer’s instructions. Cell lines and primary CLL cells 
were seeded at a concentration of 1 x 10⁶ cells/ml and 3-4 x 10⁶ cells/ml, respectively. 
Following the treatment period, the MTS reagent was added to each well, incubated for 1-2 
hours and the absorbance at 490nm was recorded on a TECAN infinite F50 reader (Labtech 
International, Uckfield, UK). Cell viability was calculated based on the reducing potential of 
the viable cells using a colourimetric reaction. Assays were performed in triplicate and 
repeated on at least two independent occasions and results were plotted and analysed using 
GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). 
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RESULTS AND DISCUSSION 
 
 
In order to characterise potential new treatments for CLL, 106 randomly selected and 41 
trisomy 12 CLL patients were sequenced for mutations in exon 34 of NOTCH1 (Figure 1A). We 
found that 12.3% patients in the random set and 29.3% in the trisomy 12 set had NOTCH1 
mutations (SNPs not included). The most common mutation was a known CT deletion in the 
PEST domain of the gene, c.7541_7542delCT (Figure S1A), which accounted for 92% of all 
coding mutations found (84.6% in the random set and all in the trisomy 12 set). In 91.3% of all 
cases it was a heterozygous mutation, while one patient had a sub-clonal population and another a 
homozygous mutation (Figure S1B). Of note, two previously unreported non-synonymous coding 
mutations were found, both contained within the TAD domain of NOTCH1. One patient had a 38 
base pair deletion (c.6906-6943del) and one a new G insertion (c.6877insG) (Figure S1C). 
Additionally, a known synonymous silent mutation (c.6870C>T) was found in the TAD of a 
patient with trisomy 12 set (Figure S1C). A number of SNPs were found, however they haven’t 
been shown to be associated with the disease or function of Notch 1 protein (data not shown). In 
summary, patients with trisomy 12 were 3.2 times more likely to have NOTCH1 mutations than 
patients without the abnormality, consistent with previous reports 18. 
 
We next studied cell sensitivity to different clinically relevant inhibitors in relation to 
their NOTCH1 status. To this end, we used Rec-1 (a Mantle cell lymphoma cell line with 
NOTCH1 mutation), Mec-1 (CLL cell line with wild type NOTCH1) and JVM3 (a B-cell 
prolymphocytic leukaemia with wild type NOTCH1). Since Notch signalling leads to activation 
of the NF-κB and BCL2 pathways 19, the drugs chosen were inhibitors of γ-secretase 
(RO4929097 and PF03084014), BCL-2 (ABT199) and NF-κB signalling (IMD0354), as well as 
BTK inhibitor (ibrutinib), currently used to treat CLL. We found that the NOTCH1 mutated 
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cell line was sensitive to RO4929097 while the wild type cells were not (Figure 1B and Table 
S5). However, this was not the case with PF03084014, which showed an unexpected 
heterogeneous response to γ-secretase inhibitors. Rec-1 was also more sensitive to IMD0354, 
but there were no differences of responses linked to NOTCH1 status in ibrutinib. Further, 
Rec-1 showed some resistance to ABT199 compared to the wild type cells, which was also 
evident in primary cells. Patient cells treated with the same drugs showed similar trends in 
mutated and wild type cells, although NOTCH1 mutants were more resistant to low 
concentrations of ABT199 or high concentrations of ibrutinib (Figure 2A). Of note, we did 
not see any differences sensitivity of NOTCH1 mutated primary cells to any of these drugs 
when stimulated to mimic the microenvironment in proliferation centres 16 (data not shown), 
suggesting that microenvironmental signals may help cells bypass the protective effects of 
mutant NOTCH1. 
 
Finally, we look at sensitivity of Rec-1 cells to combination therapies. As shown in 
Table S5, many of the combinations increased cell sensitivity to drugs when compared to 
single agent treatments. Of them, the sum of ibrutinib and RO4929097 or ABT199 were 
found to be synergistic (Figure 2B and Table S6). Contrary to this, we found antagonism 
between RO4929097 and IMD0354. These results together suggest that NOTCH1 mutated 
cells may be sensitive to certain γ-secretase inhibitors and could respond to inhibitors of 
NFκB as single agents, but they actually may be more sensitive to combination therapies, 
especially with ibrutinib. 
Cancer treatments are entering the era of precision medicine, in which therapeutic 
interventions can be tailored to individual patient’s characteristics 20. Although it has been 
accepted that the genetics of the CLL cells has a big impact on the response to treatment, little is 
known on the specific effects of NOTCH1 mutations on drug sensitivity, despite being a known 
unfavourable prognostic factor 13,21,22. Consistent with previous reports 2,4,10,11, we 
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confirmed that NOTCH1 mutations are common in our cohort and their frequency increases 
significantly with trisomy 12. Moreover, we found three new mutations in the TAD domain: a 
deletion, an insertion and a silent mutation. Based on their nature and location, we predict that the 
effects of the two frameshift mutations would be similar to the commonest NOTCH1 mutation, a 
2-base pair deletion. This could also lead to an increased resistance to intracellular NOTCH1 
degradation, its consequent accumulation in the cell and a constitutive pro-survival signalling 
activation. It is important to highlight the identification of one patient harbouring both NOTCH1 
and SF3B1 mutations, which were believed to me mutually-exclusive in the past. Although rare, 
in the recent years there have been reports of co-existence of the two 23. 
 
We also found that the NOTCH1 mutation status has an effect on the sensitivity of CLL 
cells to inhibitors of pro-survival pathways. Although γ-secretase inhibitors have been shown to 
target NOTCH1-mutant cells 24,25, we observed a different response to the two inhibitors tested, 
suggesting that there may be unknown off-target effects that may contribute to the induction of 
cell death. Moreover, mutant cells were more sensitive to inhibitors of NFκB, a pathway found to 
be upregulated in virtually all CLL patients, which highlights a specific dependence that these 
cells may have on these signals. The COSMIC database on drug sensitivity suggested that 
NOTCH1 mutated cells would be more sensitive to BCL2 inhibitors, but we found the opposite 
in both cell lines and primary cells. However, we identified two synergies a NOTCH1 mutant cell 
line: RO4929097 (γ-secretase inhibitor) and ABT199 (BCL2 inhibitor) both with ibrutinib. As 
these drugs are currently used in clinical practice, these results could potentially provide 
improved therapeutic strategies in NOTCH1-mutated patients. 
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FIGURE LEGENDS 
 
 
 
 
Figure 1. (A) Charts showing cytogenetic characteristics of patients from the Random (left) 
and Trisomy 12 (right) sets, including NOTCH1, SF3B1, IgHV, Trisomy 12, deletions of the 
long arm of chromosome 13 (13q del) and 11 (11q del) and short arm of chromosome 17, and 
recognised SNPs within NOTCH1 (126G>A and 6853G>A), with percentages over the total 
number of patients. Trisomy 12 patients were found to less likely to have a deletion in the 
long arm of chromosome 13 (odds ratio= 0.0452). No other associations were detected. (B) 
MTS viability assay of JVM3, Mec-1 and Rec-1 following 48 hours treatment with 
RO492907, PF 03084014, IMD 0354, ABT199 and ibrutinib at different concentrations. The 
statistical significance between JVM3 and Rec-1 cell line is shown by bottom line of stars 
and between Mec-1 and Rec-1 by the top line. Graph represent means of 3 experiments. Error 
bars represent standard deviation. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. 
 
 
 
 
 
Figure 2. (A) MTS viability assays of primary CLL cells after 48 hours of treatment with 
RO4929097, PF03084014, IMD 0354, ABT 199 or ibrutinib. The graphs show mean values 
of 2 measurements per patient and error bars represent standard deviations. Each circle and 
triangle represents a different NOTCH1-mutated or wild-type patient, respectively. (B) MTS 
viability assay of Rec1 treated with combinations of ibrutinib and ABT199 or RO492907. 
Error bars represent standard deviation. The statistical significance between single agent 
treatment and combinations are shown by the stars at the bottom. * P ≤ 0.05; ** P ≤ 0.01; *** 
P ≤ 0.001; **** P ≤ 0.0001. 
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SUPPLEMENTARY INFORMATION 
 
 
 
 Random set Trisomy 12 set 
Number of patients 106 41 
Female to male ratio 1:1.625 1:1.6 
Median age at diagnosis 62 years 68 years 
Age range 33 to 86 years 42 to 92 years 
Mutated IgHV 60.82% 55.9% 
Chromosomal abnormalities 85% 100% 
13q del 46.43% 17.1% 
Trisomy 12* 15.48% 100% 
11q del 16.6% 2.4% 
17p del 3.57% 2.4% 
Other chromosomal 16.67% 19.51% 
abnormalities   
   
 
Table S1. Characteristics of the sets of patient samples used in the study. Cytogenetic 
data was only available for 84 out of the 106 patients of the Random set. 
 
 
  NOTCH1 Primers 
Set 1 Forward  5’- ATGGCTACCTGTCAGACGTG 
 Reverse  5’- TCTCCTGGGGCAGAATAGTG 
Set 2 Forward  5’- GAGCTTCCTGAGTGGAGAGC 
 Reverse  5’- CCTGGCTCTCAGAACTTGCT 
 
Table S2. Primers used for sequencing NOTCH1 mutations. 
 
 
 
 
 Inhibitor  Target  Supplier 
 
      
 
 RO4929097  
Gamma-Secretase Complex 
 Generon (A4005) 
 
     
 
 
PF-03084014 
  
Selleckchem (S8018) 
 
    
 
      
 
 ABT 199  BCL2  Selleckchem (S8048) 
 
      
 
 
IMD 0354 
 NFκB pathway (IκBβ phosphorylation  
Stratech (S2864)    inhibitor)        
 
 Ibrutinib  BTK  Stratech (S2680) 
 
      
 
  
Table S3. Targeted inhibitors used in this study. 
  JVM3  Mec-1  Rec-1 
 
       
 
RO4929097  >10µM  > 10µM  5.51 µM 
 
       
 
PF 03084014  >10 µM  >10 µM  >10 µM 
 
       
 
  
5.05 µM 
 
5.13 µM 
 
1.54 µM 
 
IMD 0354    
 
       
 
ABT 199  1.90 µM  4.57 µM  4.67 µM 
 
       
 
  
>10 µM 
 
4.65 µM 
 
3.65 µM 
 
Ibrutinib    
 
       
 
 
Table S4. Table summarising the IC50 values for inhibitors tested in each cell line, with the 
values suggesting an increased sensitivity in NOTCH1 mutant cells highlighted in green and 
decreased sensitivity in red.  
 
 
 Constant                
 
 inhibitor  RO   PF  IMD	
0354 
  
ABT	199 
  
Ibrutinib 
 
 
    
4929097 
  0308401
4 
       
 
 
Variable 
     (0.1uM)   (0.1uM)    (0.1uM)      (0.1uM)   (0.1uM)                        
 
 inhibitor                
 
 RO	4929097 5.51   >10  >10   5.53   1.41  
 
                 
  
PF	03084014 >10 >10 >10 5.56  <0.001 
       
IMD	0354 4.23  3.51 1.54 3.9  0.54 
        
ABT	199 2.76  2.99 4.93 4.67 <0.001 
        
Ibrutinib <0.001  1.57 3.28 <0.001 3.6 
       
 
Table S5. Chart showing IC50 values (µM) of drugs in combination therapies in Rec-1, using 
a constant inhibitor at 0.1 µM (top row) and a variable inhibitor (left-hand column). IC50 
values for each drug as a single agent are highlighted in bold (white background). Increased 
sensitivity to the variable drug in comparison to IC50 of the drug alone is highlighted in 
green, a decreased sensitivity in red, no relevant change in grey. 
 Variable                 
 
 inhibitor   
RO 
  
PF 
  
IMD 
  
ABT199 
  
Ibrutinib 
 
 
 
Constant 
           
 
                 
 
 inhibitor                 
 
 RO   n/s  n/s  n/s  0.815   0.068  
 
                  
 
 PF   n/s  n/s  n/s  n/s  n/s 
 
                  
 
 IMD   n/s  n/s  n/s  n/s  n/s 
 
                  
 
 ABT199   4.4   n/s  n/s  n/s  0.032  
 
                  
 
 Ibrutinib   0.436   n/s  n/s  0.082   n/s 
 
                  
  
 
Table S6. Combination Index (CI) values calculated using the CalcuSyn software. CI is used 
as an indication of synergy, as follows: < 0.1, Very strong synergism; 0.1–0.3, Strong 
synergism; 0.3–0.7, Synergism; 0.7–0.85, Moderate synergism; 0.85–0.9, Slight synergism; 
0.90–1.1, Nearly additive; 1.1–1.2, Slight antagonism; 1.2–1.45, Moderate antagonism; 1.45– 
3.3, Antagonism; 3.3–10, Strong antagonism;>10, Very strong antagonism. In green, 
synergistic combinations. In red, antagonistic combinations. n/s: not significant. 
SUPPLEMENTARY FIGURE LEGENDS 
 
 
Figure S1. (A) Chromatograms showing sequencing of the NOTCH1 PEST domain. The 2 
base pair CT deletion in the PEST domain (c.7541_7542delCT) shown by the red arrow was 
the most frequent (#1). The frameshift mutation causes amino acid change and a premature 
stop codon to be inserted. The mutation was heterozygous in 91.3% of the patients, as seen in 
this example. The CT deletion was also seen at a sub-clonal population level (#2) and as a 
homozygous mutation (#3). A chromatogram of a patient with wild-type NOTCH1 is shown 
as reference (#4). (B) Chromatogram showing NOTCH1 sequencing results of patient with a 
silent single cytosine (C) to thymine (T) nucleotide substitution (red arrow). (C) 
Chromatogram showing NOTCH1 sequencing of a patient with a 38 base pair deletion 
(c.6906-6943del CAGTTTGAATGG TCAATGCGAGTGGCTGTCCCGGCTGC) (top) and 
patient with c.6877insG (bottom). The original nucleotide sequence and the shifted sequence 
are shown below the chromoatograms. 
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